




## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : C12N 15/62, 15/13, 15/14, 15/12 C07K 13/00, A61K 39/395, 37/02 C12N 5/10		A3	(11) International Publication Number: <b>WO 91/08298</b>
			(43) International Publication Date: 13 June 1991 (13.06.91)
<p>(21) International Application Number: PCT/US90/06849</p> <p>(22) International Filing Date: 21 November 1990 (21.11.90)</p> <p>(30) Priority data: 444,625 22 November 1989 (22.11.89) US</p> <p>(71) Applicant: GENENTECH, INC. [US/US]; 460 Point San Bruno Boulevard, South San Francisco, CA 94080 (US).</p> <p>(72) Inventors: CAPON, Daniel, J. ; 817 Oregon Street, San Mateo, CA 94402 (US). LASKY, Laurence, A. ; Star Route Box 460, Sausalito, CA 94965 (US).</p> <p>(74) Agents: ADLER, Carolyn, R. et al.; Genentech, Inc., 460 Point San Bruno Boulevard, South San Francisco, CA 94080 (US).</p>		<p>(81) Designated States: AT (European patent), BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent).</p> <p><b>Published</b> With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</p>	
		<p>(88) Date of publication of the international search report: 17 October 1991 (17.10.91)</p>	

(54) Title: **FUSION PROTEINS CONSISTING OF A LIGAND BINDING PROTEIN AND A STABLE PLASMA PROTEIN**

### *Murine PLN Homing Receptor IgG Chimeras*



(57) Abstract

Novel polypeptides are provided, together with methods for making and using them, and nucleic acids encoding them. These polypeptides are useful as cell surface adhesion molecules and ligands, and are useful in therapeutic or diagnostic compositions and methods.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	CN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark				

# INTERNATIONAL SEARCH REPORT

International Application No PCT/US 90/06849

## I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all)<sup>6</sup>

According to International Patent Classification (IPC) or to both National Classification and IPC

IPC5: C 12 N 15/62, 15/13, 15/14, 15/12, C 07 K 13/00  
A 61 K 39/395, 37/02, C 12 N 5/10

## II. FIELDS SEARCHED

Minimum Documentation Searched<sup>7</sup>

Classification System	Classification Symbols
IPC5	C 12 N; C 07 K; A 61 K
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in Fields Searched <sup>8</sup>	

## III. DOCUMENTS CONSIDERED TO BE RELEVANT<sup>9</sup>

Category <sup>10</sup>	Citation of Document <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>
E	WO, A1, 9104329 (ABBOTT LABORATORIES) 4 April 1991, see especially p.14 line 33-p. 15 line 15 --	1-5, 9- 11, 13- 17, 19- 22, 42- 49
E	EP, A2, 0414178 (THE GENERAL HOSPITAL CORPORATION) 27 February 1991, see the whole document --	1-5, 7- 11, 13- 29, 40- 49
E	EP, A1, 0413622 (RHONE-POULENC SANTE) 20 February 1991, see the whole document --	1, 34- 49

\* Special categories of cited documents: 10

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed


"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"S" document member of the same patent family

## IV. CERTIFICATION

Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report
27th August 1991	13.09.91
International Searching Authority EUROPEAN PATENT OFFICE	Signature of Authorized Officer Falk Heck 

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
E	WO, A1, 9100360 (MEDAREX, INC.) 10 January 1991, see the whole document  --	1-5,7- 11,13- 29,40- 49
E	WO, A1, 9014103 (SCRIPPS CLINIC AND RESEARCH FOUNDATION) 29 November 1990, see the whole document  --	1-5,7- 11,13- 29,40- 49
E	EP, A1, 0399666 (DELTA BIOTECHNOLOGY LIMITED) 28 November 1990, see the whole document  --	1,34- 49
P,X	EP, A1, 0394827 (F. HOFFMANN-LA ROCHE AG) 31 October 1990, see the whole document  --	1-5,7- 11,13- 29,40- 49
P,X	EP, A2, 0391088 (THE CENTER FOR BLOOD RESEARCH) 10 October 1990, see especially claims 12-13  --	1-5,7- 11,13- 29,40- 49
P,A	EP, A1, 0386906 (DANA FARBER CANCER INSTITUTE) 12 September 1990, see the whole document  --	6,12,27, 30-33, 36
P,X	WO, A1, 9005144 (MEDICAL RESEARCH COUNCIL) 17 May 1990, see especially claims 1-5  --	1-5,7- 11,13- 29,40- 49

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
P,X	WO, A1, 9002338 (THE GENERAL HOSPITAL CORPORATION) 8 March 1990, see the whole document	1-5,7- 11,13- 21,40- 49
	---	
P,X	EP, A2, 0346316 (KABIGEN AB) 13 December 1989, see the whole document	1-5,7- 11,13- 21,40- 49
	---	
X	EP, A3, 0325262 (THE GENERAL HOSPITAL CORPORATION) 26 July 1989, see the whole document	1-5,7- 11,13- 29,40- 49
Y		1,34- 49
	---	
X	EP, A2, 0325224 (ZYMOGENETICS INC.) 26 July 1989, see the whole document	1-5,7- 11,13- 29,40- 49
Y		1,34- 49
	---	
Y	EP, A1, 0322094 (DELTA BIOTECHNOLOGY LIMITED) 28 June 1989, see the whole document	1,34- 49
	---	
X	EP, A1, 0314317 (GENENTECH, INC.) 3 May 1989, see especially the abstract, p. 4 line 57-p. 5, line 2, the claims	1-5,7- 11,13- 49
	---	
Y	EP, A1, 0308381 (SKANDIGEN AB ET AL.) 22 March 1989, see the whole document	1,34- 49
	---	

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
X	EP, A2, 0294703 (DANA-FARBER CANCER INSTITUTE, INC.) 14 December 1988, see the whole document	1-5,8- 11,13- 17,42- 49
X	EP, A1, 0288809 (HOECHST AKTIENGESELLSCHAFT) 2 November 1988, see the whole document	1,42- 49
X	EP, A2, 0271227 (THE GENERAL HOSPITAL CORPORATION) 15 June 1988, see the whole document	1-5,8- 11,13- 17,42- 49
X	EP, A2, 0207402 (BAYER AG) 7 January 1987, see especially claims 6 and 10	1-5,8- 11,13- 17,42- 49
X	EP, A1, 0125023 (GENENTECH, INC.) 14 November 1984, see especially p. 29 lines 7-20	1-5,8- 11,13- 17,42- 49
P,X	J. Cell. Biochem. Suppl. 0 (14 part B), 1990, see page 84, abstract CE217, S.R. Watson et al.: "Characterization and activities of murine peripheral lymph node homing receptor"	1-5,7- 11,13- 21,42- 49
A	Letters to Nature, vol. 342, November 1989, D. Camerini et al.: "Leu-8/TQ1 is the human equivalent of the Mel-14 lymph node homing receptor ", see page 78 - page 82	6,12,27, 30-33, 36

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
A	Proc. Natl. Acad. Sci., vol. 86, July 1989, M.H. Siegelman et al.: "Human homologue of mouse lymph node homing receptor: Evolutionary conservation at tandem cell interaction domains", see page 5562 - page 5566 --	6,12,27, 30-33, 36
A	The Journal of Cell Biology, vol. 109, July 1989, B.R. Bowen et al.: "Characterization of a human homologue of the murine peripheral lymph node homing receptor", see page 421 - page 427 --	6,12,27, 30-33, 36
X	Letters to Nature, vol. 339, May 1989, A. Traunecker et al.: "Highly efficient neutralization of HIV with recombinant CD4-immunoglobulin molecules", see page 68 - page 70 --	1-5,7- 11,13- 29,42- 49
X	Nature, vol. 337, February 1989, D.J. Capon et al.: "Designing CD4 immunoadhesins for AIDS therapy", see page 525 - page 531 --	1-5,7- 11,13- 29,42- 49
Y	Chemical Abstracts, volume 109, no. 25, 19 July 1988, (Columbus, Ohio, US), Reed, Roberta G. et al.: "Non-resolving jaundice: bilirubin covalently attached to serum albumin circulates with the same metabolic half-life as albumin", see page 587, abstract 227803g, & Clin. Chem. 1988, 34(10), 1992-1994 --	1,34- 49
X	Nature, vol. 312, December 1984, M. S. Neuberger et al.: "Recombinant antibodies possessing novel effector functions", see page 604 - page 608 -- -----	1-5,8- 11,13- 21,42- 49

## FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

V.  OBSERVATION WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE 1

This International search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claim numbers  
Authority, namely because they relate to subject matter not required to be searched by this

2.  Claim numbers 1-5,7-11,13-26,28,29,34-49 because they relate to parts of the International application that do not comply with the prescribed requirements to such an extent that no meaningful International search can be carried out, specifically:  
for further information see form PCT/ISA/206 dd 16/04/91

3.  Claim numbers  
the second and third sentences of PCT Rule 6.3(a) because they are dependent claims and are not drafted in accordance with

VI.  OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING 2

This International Searching Authority found multiple inventions in this International application as follows:  
1. claims 6,12 completely,(1-5,8-11,13-22,40,42-49)partially; 2. claims 7 completely,(1-5,8-22,40,42-29)partially; 3. claims 23 completely,(1-5,8-22,40,42-49)partially; 4. claims 24 completely,(1-5,8-22,40,42-49)partially; 5. claims 25-33; 6. claims 34,35,39; 7. claims 38,41

for further information see form PCT/ISA/206 dd 16/04/91

1.  As all required additional search fees were timely paid by the applicant, this International search report covers all searchable claims of the International application

2.  As only some of the required additional search fees were timely paid by the applicant, this International search report covers only those claims of the International application for which fees were paid, specifically claims:

3.  No required additional search fees were timely paid by the applicant. Consequently, this International search report is restricted to the invention first mentioned in the claims, it is covered by claim numbers

4.  As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee

## Remark on Protest

The additional search fees were accompanied by applicant's protest  
 No protest accompanied the payment of additional search fees

**ANNEX TO THE INTERNATIONAL SEARCH REPORT  
ON INTERNATIONAL PATENT APPLICATION NO.PCT/US 90/06849**

SA 43043

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.  
The members are as contained in the European Patent Office EDP file on 27/06/91  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO-A1- 04329	04/04/91	NONE		
EP-A2- 0414178	27/02/91	AU-D- WO-A-	6429590 91/02743	03/04/91 07/03/91
EP-A1- 0413622	20/02/91	FR-A-	2650598	08/02/91
WO-A1- 9100360	10/01/91	AU-D-	5962290	17/01/91
WO-A1- 9014103	29/11/90	AU-D-	5815990	18/12/90
EP-A1- 0399666	28/11/90	EP-A- WO-A-	0407008 90/13306	09/01/91 15/11/90
EP-A1- 0394827	31/10/90	JP-A-	3035781	15/02/91
EP-A2- 0391088	10/10/90	AU-D- JP-A- AU-D-	5129490 3072430 5117290	20/09/90 27/03/91 13/09/90
EP-A1- 0386906	12/09/90	CA-A- JP-A-	2010321 3022982	21/08/90 31/01/91
WO-A1- 9005144	17/05/90	AU-D- EP-A-	4520189 0368684	28/05/90 16/05/90
WO-A1- 9002338	08/03/90	EP-A-	0355068	21/02/90
EP-A2- 0346316	13/12/89	JP-A-	2072199	12/03/90
EP-A3- 0325262	26/07/89	AU-D- WO-A-	3281889 89/06690	11/08/89 27/07/89
EP-A2- 0325224	26/07/89	AU-D- JP-A-	2866889 2031688	27/07/89 01/02/90
EP-A1- 0322094	28/06/89	AU-D- JP-A-	2404688 2000194	18/05/89 05/01/90
EP-A1- 0314317	03/05/89	AU-D- EP-A-	2557188 0383799	18/04/89 29/08/90
EP-A1- 0308381	22/03/89	AU-D- JP-T-	2420488 3501323	17/04/89 28/03/91

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

**ANNEX TO THE INTERNATIONAL SEARCH REPORT  
ON INTERNATIONAL PATENT APPLICATION NO.PCT/US 90/06849**

SA 43043

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.  
The members are as contained in the European Patent Office EDP file on **27/06/91**  
The European Patent office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP-A1- 0308381	22/03/89	SE-B-	459586	17/07/89
		SE-A-	8703539	15/03/89
		WO-A-	89/02467	23/03/89
EP-A2- 0294703	14/12/88	JP-A-	64003128	06/01/89
EP-A1- 0288809	02/11/88	AU-D-	1466188	20/10/88
		DE-A-	3712985	03/11/88
		JP-A-	63301898	08/12/88
		ZA-A-	8802659	14/10/88
EP-A2- 0271227	15/06/88	JP-T-	500950	05/04/90
		WO-A-	88/03559	19/05/88
EP-A2- 0207402	07/01/87	DE-A-	3523701	08/01/87
		JP-A-	62014795	23/01/87
EP-A1- 0125023	14/11/84	AU-B-	598441	28/06/90
		AU-D-	2642984	11/10/84
		AU-D-	5201390	30/08/90
		CA-A-	1218613	03/03/87
		JP-A-	60155132	15/08/85
		US-A-	4816567	28/03/89

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>C12N 15/62, C07K 14/71, A61K 38/17</b>		A1	(11) International Publication Number: <b>WO 98/48024</b> (43) International Publication Date: <b>29 October 1998 (29.10.98)</b>
<p>(21) International Application Number: <b>PCT/US98/07587</b></p> <p>(22) International Filing Date: <b>16 April 1998 (16.04.98)</b></p> <p>(30) Priority Data: 60/044,641 <b>18 April 1997 (18.04.97)</b> US</p> <p>(71) Applicant (<i>for all designated States except US</i>): <b>BIOGEN, INC.</b> [US/US]; 14 Cambridge Center, Cambridge, MA 02142 (US).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (<i>for US only</i>): <b>GOTWALS, Philip</b> [US/US]; 692 LaGrange Street, West Roxbury, MA 02132 (US). <b>KOTELIANSKY, Victor</b> [US/US]; 1 Longfellow Place, Boston, MA 02215 (US). <b>CATE, Richard</b> [US/US]; 64 Arrowhead Road, Weston, MA 02193 (US). <b>SAN-ICOLA-NADEL, Michelle</b> [US/US]; 4 Maple Road, Winchester, MA 01890 (US).</p> <p>(74) Agent: <b>KAPLAN, Warren, A.</b>; Biogen, Inc., 14 Cambridge Center, Cambridge, MA 02142 (US).</p>		<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p><b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>	
<p>(54) Title: <b>TYPE II TGF-BETA RECEPTOR/IMMUNOGLOBULIN CONSTANT REGION FUSION PROTEINS</b></p> <p>(57) Abstract</p> <p>Fusion proteins comprising the TGF-beta Type II receptor linked to a portion of an immunoglobulin constant chain are described. Also described are methods of using the fusion proteins of the invention to treat a variety of fibroproliferative disorders.</p>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## TYPE II TGF-BETA RECEPTOR/IMMUNOGLOBULIN CONSTANT REGION FUSION PROTEINS

BACKGROUND OF THE INVENTION

5 The present invention relates to soluble TGF-beta receptor fusion proteins and to their uses in treating conditions characterized by an overproduction of TGF- beta , including fibroproliferation

## BACKGROUND

10 Transforming growth factor- beta (TGF- beta ) represents a family of polypeptides, of which three are present in mammals, TGF- beta 1, TGF- beta 2 and TGF- beta 3. These factors have global effects on cell growth and differentiation (Roberts and Sporn (1990) Handbk. Exp. Pharm. 95:419-58). There is a growing body of evidence that TGF- beta also modulates the 15 immune process (Wahl et al. (1989) Immunol. Today 10:258-61). In addition to stimulating the congregation of immune cells at the site of injury, TGF- beta also provides strong positive feedback for its own continued synthesis (Kim et al. (1990) Mol.Cell. Biol. 10:1492-1497).

15 TGF- beta may be a prominent factor in the etiology of fibroproliferative disorders. TGF- beta is known to stimulate cells to produce more proteins, including collagen, biglycan, decorin and fibronectin; and to inhibit enzymes which degrade these proteins. Thus, TGF- beta can cause fibrous tissue to accumulate. For example, in diabetic nephropathy and human mesangial proliferative glomerulonephritis, both fibroproliferative disorders, a prominent and important pathological feature is the accumulation of mesangial matrix (Mauer et al. (1984) J. Clin. Invest. 74: 1143-55). Likewise, postradiation fibrosis is characterized by excess TGF- beta . 20 25 proliferation of fibroblasts and overproduction of connective tissue (Canney and Dean (1990) Brit. J. Radiol. 63:620-23). Workers in the field have attempted to suppress the effects of TGF- beta by administering anti-TGF-beta antibody. See Border et al. (1990) Nature 346:371-74; Border et al. ((1992) Kidney Int. 41:566-570).

30 The biological effects of TGF-beta are mediated by several specific cell surface proteins, including the so-called type I, type II, and type III TGF-beta receptors. Most of these were initially identified by chemically crosslinking radio iodinated TGF-beta to cell surface proteins using the bifunctional reagent DSS. Almost all TGF-beta responsive cell lines express both the type I and type II receptors, although the levels of their expression may vary among

different cell types. Neither type I nor type II receptor in the absence of the other can mediate a TGF-beta response, although the type II receptor alone is capable of binding TGF-beta.

In developing improved TGF-beta inhibitors to treat fibroproliferative disorders, it is important to consider that such inhibitors should have a much lower molecular weight and 5 higher affinity than anti-TGF-beta antibodies. This combination of features would permit much lower doses and increase ease of administration. Moreover, a native protein would not cause cross-species reactions.

#### SUMMARY OF THE INVENTION

10 Accordingly, the present invention is directed to novel compositions and methods for the therapeutic treatment of patients having fibroproliferative disorders..

The invention also is directed to recombinant DNA vectors and methods of use thereof. The vectors allow expression of TGF- beta receptor fusion proteins in bacterial and mammalian host cells.

15 One embodiment of the invention is an isolated TGF-beta receptor fusion protein that competitively inhibits binding of TGF-beta to TGF-beta receptor. Preferably, this protein is a TGF-beta Type II receptor linked to a second protein that is not a TGF-beta Type II receptor in which the second protein is a constant region of an immunoglobulin. Other preferred proteins contain the novel amino acid sequences of SEQ ID NOS: 11 and 13 which encompass the 20 region of the fusion on either side of the TGF-beta receptor/immunoglobulin junction.

Isolated polynucleotides are also embodied herein, encoding, on expression, for an TGF-beta Type II receptor linked to a second protein that is not a TGF-beta Type II receptor. The preferred polynucleotides are selected from the group consisting of: (a) SEQ ID NOS.: 1, 2, 3, 4, 10 and 12; (b) polynucleotides that hybridize to these sequences under standard hybridization 25 conditions and that encodes a protein having the TGF-beta inhibitory activity of a TGF-beta Type II receptor fusion protein; and (c) polynucleotides that code on expression for a protein encoded by any of the foregoing polynucleotide sequences.

Pharmaceutical compositions of the invention are exemplified by a TGF-beta receptor fusion protein in a pharmaceutically acceptable carrier, the fusion protein in an amount 30 sufficient to competitively inhibit binding of TGF-beta to a TGF-beta ligand.

Methods of the invention include a method for producing a TGF-beta receptor fusion protein, comprising culturing a host cell containing a vector of the invention, allowing said cell to express the fusion protein, isolating and purifying the fusion protein.

-3-

One embodiment is a method for lowering the levels of TGF-beta in an individual which comprises administering to the individual an effective amount of a TGF-beta antagonist that is a TGF-beta receptor fusion protein comprising the sequence of amino acids of SEQ ID NOS: 8, 9, 11 and 13.

5 Another embodiment is a method for lowering the levels of TGF-beta in an individual having arthritis, which comprises administering to the individual an effective amount of a TGF-beta antagonist that is a TGF-beta receptor fusion protein comprising the sequence of amino acids of SEQ ID NOS: 8, 9, 11 and 13.

10 In one embodiment, the invention provides a method for treating an individual for a medical condition associated with a fibroproliferative disorder. The method provides for the parenteral, oral or local administration of a sufficient amount of soluble TGF- beta - receptor fusion protein to the individual to reduce or ameliorate the disorder and/or block activity of TGF- beta activity in the individual.

15 In yet another embodiment, the method of the present invention provides for TGF- beta receptor fusion protein administration by intravenous, intraocular, intraarticular, transdermal and enteral methods. In another embodiment of the present invention, the TGF- beta receptor fusion protein is administered to patients with collagen vascular disorders, such as systemic sclerosis, polymyositis, scleroderma, dermatomyositis, or systemic lupus erythematosus.

20 In yet another embodiment of the present invention, the TGF- beta receptor fusion protein is administered to patients with intraocular and pulmonary fibrosis. In a further embodiment, the TGF- beta receptor fusion protein is administered to patients with diabetic nephropathy, glomerulonephritis, proliferative vitreoretinopathy, and rheumatoid arthritis.

25 In still another embodiment, the method of the present invention provides for treating a wound in an individual to avoid overproduction of connective tissue formation which is associated with upregulation of TGF- beta. The method provides for administration of a sufficient amount of TGF- beta receptor fusion protein to the individual to reduce the amount or activity of TGF- beta in the individual. In further embodiments, the types of wounds include surgical incisions, trauma-induced lacerations and wounds involving the peritoneum for which the overproduction of connective tissue formation is abdominal adhesions. In a further embodiment, the overproduction of connective tissue formations which are avoided include scars, including those where the scar involves restenosis of blood vessels, and hypertrophic scars, and keloids.

In another embodiment, the invention provides a method of preventing postradiation fibrosis in an individual undergoing or about to undergo radiation therapy. TGF- beta receptor fusion protein is administered in an amount sufficient to prevent overproduction of fibrous tissue formation.

5

It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory and are intended to provide further explanation of the invention as claimed. The accompanying drawings are included to provide a further understanding of the invention and are incorporated in and constitute a part of this specification, illustrate several embodiments of the invention, and together with the description serve to explain the principles of the invention.

#### LIST OF THE SEQUENCES

15

SEQ ID NO: 1 Nucleotide Sequence of the Rabbit TGF $\beta$ RII:Fc Expression Vector

20

1 GAATTCGAGC TTGCATGCCT GCAGGTCGTT ACATAACTTA CGGTAAATGG

51 CCCGCCTGGC TGACCGCCCA ACGACCCCCG CCCATTGACG TCAATAATGA

101 CGTATGTTCC CATACTAACG CCAATAGGGA CTTTCCATTG ACGTCAATGG

151 GTGGAGTATT TACGGTAAAC TGCCCCTTG GCAGTACATC AAGTGTATCA

201 TATGCCAAGT ACGCCCCCTA TTGACGTCAA TGACGGTAAA TGGCCCGCCT

251 GGCATTATGC CCAGTACATG ACCTTATGGG ACTTTCTAC TTGGCAGTAC

301 ATCTACGTAT TAGTCATCGC TATTACCATG GTGATGCCGT TTTGGCAGTA

351 CATCAATGGG CGTGGATAGC GGTTTGACTC ACGGGGATTT CCAAGTCTCC

401 ACCCCCATTGA CGTCAATGGG AGTTTGTTT GGCAACAAAA TCAACGGGAC

451 TTTCCAAAAT GTCGTAACAA CTCCGCCCA TTGACGCAA TGGCCGGTAG

501 GCGTGTACGG TGGGAGGTCT ATATAAGCAG AGCTCGTTA GTGAACCGTC

551 AGATCGCCTG GAGACGCCAT CCACGCTGTT TTGACCTCCA TAGAAGACAC

601 CGGGACCGAT CCAGCCTCCG GACTCTAGAG GATCCGGTAC TCGAGGAAC

651 GAAAAACCAAG AAAGTTAACT GGTAAGTTA GTCTTTTGT CTTTTATTTC

701 AGGTCCCCGA TCCGGTGGTG GTGCAAATCA AAGAACTGCT CCTCAGTGG

50

751 TGTTGCCTTT ACTTCTAGGC CTGTACGGAA GTGTTACTTC TGCTCTAAAA

-5-

5	801	GCTGCGGAAT TGTACCCGCG GCCGCTCTGC CATGGGTCGG GGGCTGCTCC
	851	GGGGCCTGTG GCCGCTGCAC CTCGTCTGT GGACGCGCAT CGCCAGCACG
10	901	ATCCCGCCGC ACGTCAGAA GTCGGTTAAT AACGACATGA TGGTCACGGA
	951	CAACAATGGC GCCGTCAAGT TCCCACAAC GTGCAAGTTT TGCGATGTGC
15	1001	GATCTTCCAC CTGTGACAAC CAGAAGTCCT GCATGAGCAA CTGCAGCATC
	1051	ACGTCCATCT GTGAGAAGGC ACACGAAGTC TGCGTGGCCG TCTGGAGGAA
20	1101	GAACGATGAA AACATAACCC TGGAGACTGT GTGTCACGAC CCCAAGCTCG
	1151	CCTACCATGG ATTCTTCTG GAAGATTCTG CCTCTCCAAA GTGTATCATG
25	1201	AAAGAAAAGA AGGTGTTGG GGAGACTTTC TTCATGTGTT CCTGCAGCAC
	1251	TGACCGAGTGC AATGACCACA TCATCTTCTC TGAGGAATAC ACCACCAGCA
30	1301	GTCCGGATCT GGTCGACAAA ACTCACACAT GCCCACCGTG CCCAGCACCT
	1351	GAACTCCTGG GGGGACCGTC AGTCTTCTC TTCCCCCAA AACCCAAGGA
35	1401	CACCCCTCATG ATCTCCCGA CCCCTGAGGT CACATGCGTG GTGGTGGACG
	1451	TGAGCCACGA AGACCCGTAG GTCAAGTTCA ACTGGTACGT GGACGGCGTG
40	1501	GAGGTGCATA ATGCCAAGAC AAAGCCGCGG GAGGAGCAGT ACAACAGCAC
	1551	GTACCGTGTG GTCAGCGTCC TCACCGTCCT GCACCAAGGAC TGGCTGAATG
45	1601	GCAAGGAGTA CAA GTGCAAG GTCTCCAACA AAGCCCTCCC AGCCCCCATC
	1651	GAGAAAACCA TCTCCAAAGC CAAAGGGCAG CCCCAGAAC CACAGGTGTA
50	1701	CACCCCTGCC CCATCCCGGG ATGAGCTGAC CAAGAACCAAG GTCAGCCTGA
	1751	CCTGCCTGGT CAAAGGCTTC TATCCAGCG ACATGCCGT GGAGTGGGAG
55	1801	AGCAATGGGC AGCCGGAGAA CAACTACAAG ACCACGCCCTC CCGTGTGTTGGA
	1851	CTCCGACGGC TCCTTCTTCC TCTACAGCAA GCTCACCGTG GACAAGAGCA
60	1901	GGTGGCAGCA GGGGAACGTC TTCTCATGCT CCGTGTGCA TGAGGCTCTG
	1951	CACAACCAC ACTACGCAGAA GAGCCTCTCC CTGTCTCCGG GTAAATGAGT
65	2001	GCggccgcGT CGACCGTGAC CCCTGCGCCG CGCGGACTCC TGCCCCGAGG
	2051	GTCCGGACGC GCCCCAGCTC GCGCCCCCTTC CCATATTTAT TCGGACCCCA
70	2101	AGCATCGCCC CAATAAAAGAC CAGCAAGCAA CCGGCTGGGG TGTCCGTGCG
	2151	TGTTAGGGGG CCCGTGGGAC CTCCCTTGCC GTCTCTCCTC GCGCACGGCC
75	2201	CGGGTCCGCC CTGTAGCGCT CGCTGTCTCTC CCCCTGCTG AAGCGCCCCA
	2251	CCACCGTCTT TCAGGCCCCG GACTTGGTGC CGGGTCCAGG CGTAAAGGAG
80	2301	CAGGTGACTC TGCGCAGCAC TCGCTTTATT TCGCCAGAGT CGCGGGCGT

-6-

2351 CCAGAAGGGG CCCCTGGACT CGGGCGCGGG GCGGGCTCAG TCCCCCCCC  
 2401 TGCCTGCGCG GAGCTTCTGG CGACTCCAG GCGCTGCTC CTCGTCGG  
 5 2451 CGCCTCGGGG ACACCCAGGC CTGCTTCTTC CTGGGCTCGG CGTCCCTGGA  
 2501 GTCCCCTGCC CACGGCCGGT GGCCCCCTTC GCGTGACTCC CAGCGCTGGG  
 10 2551 GTAGGGCTTC CCGGGGCTCC CTGGCGGCC CGTGGCTCTC CTCTTCCGC  
 2601 GGCCTCTCTT TCTTAGGTCT CTCTCTCTTC CGCGGCTCT CGTCCCGCG  
 15 2651 CTTCCCCCTCT CTCCGAGGCC TCTCCTTGGG TCCCCGGTCT GCGAGGGTCA  
 2701 CACGGTCCTC CCGGACGGCC TCTCCGGTGG CCTCGCCGGG CTCCCTCTCG  
 2751 TCGTTCTCTG CAGCCTCCCG ACTCCCGGGA ATCTTGGTC TGACCTCTGC  
 20 2801 CTCGGCCCGG GGCGCAGGCG GCGCTGATGG AGGCGCCTGG GCCTCGAACT  
 2851 TAGGCTGCAA GACAGAGTGG GGTCTGGGG TAAGCGCCCA CGTCCCCCCC  
 2901 GGCCCGGGCT CCTTCTTCTC TTGGGGATGA AGGTCCAAT GCGCGGGTC  
 25 2951 AGTGGAAAGGA AGCTCTTACG AGGGGGGACG ATGGCTCCCT CGGGGCTGAG  
 3001 CTTGGCGGGGA CCCAGGGCTC GGGCACACGT GCTTGGAGTG CTGCCTCCGC  
 3051 AGGGACGGCG TCTGCAGCGA CAGGGTCGGG ACCCGAGTCA GCTGGCCGA  
 30 3101 GGCACGGTCC ACACGTCCA TCCCTCCCTC ACCCCTAGAG CGCCCGTCCC  
 3151 TGGACAGTTG GAGTGGGGCT CGCCCGGTAC GGCTGAGACT AAGGATGCC  
 35 3201 CCGAGCCGTG GGAAGGGACT CGGGGACTCC GCTGCCGGG CGCCCGTTCT  
 3251 CCGAACCTCG CTCTTCAAT TGGTCATTCT TCCCCCGAC CACGGCTGT  
 40 3301 AGGAGGCCCC TAGCAAGGGA GGGGTCGCAG GAGTGCCCCC GGGGGCGCT  
 3351 CACGAGCTGA GCGGTCCCCA GAGAGGGCGC AGGGGAAAGG CGGCAGAACG  
 3401 CTACGAGGCA GGAGGGTTG CACAAGGTC ATCCGGAAGC CAGAACCTAC  
 45 3451 TCGCGCGAG GGGATGGC CCCGCAAAG GTCCACACCG GGTGAGAGGG  
 3501 GCGCGCAAGG CCCGTCActt aagggacata TGACGTGAGC TCAGATCTT  
 3551 GTGAAGGAAC CTTACTTCTG TGGTGTGACA TAATTGGACA AACTACCTAC  
 50 3601 AGAGATTTAA AGCTCTAAGG TAAATATAAA ATTTTTAAGT GTATAATGTG  
 3651 TTAAACTACT GATTCTAATT GTTTGTGTAT TTTAGATTCC AACCTATGGA  
 55 3701 ACTGATGAAT GGGAGCAGTG GTGGAATGCC TTTAATGAGG AAAACCTGTT  
 3751 TTGCTCAGAA GAAATGCCAT CTAGTGATGA TGAGGCTACT GCTGACTCTC  
 3801 AACATTCTAC TCCTCCAAAA AAGAAGAGAA AGGTAGAAGA CCCCAAGGAC  
 60 3851 TTTCTTCAG AATTGCTAAG TTTTTTGAGT CATGCTGTGT TTAGTAATAG  
 3901 AACTCTTGCT TGCTTGCTA TTTACACCAAC AAAGGAAAAA GCTGCACTGC

3951	TATACAAGAA AATTATGGAA AAATATTCTG TAACCTTTAT AAGTAGGCAT
4001	AACAGTTATA ATCATAACAT ACTGTTTTTT CTTACTCCAC ACAGGCATAG
5 4051	AGTGTCTGCT ATTAATAACT ATGCTAAAA ATTGTGTACC TTTAGCTTTT
4101	TAATTTGTAA AGGGGTTAAT AAGGAATATT TGATGTATAG TGCCCTGACT
10 4151	AGAGATCATA ATCAGCCATA CCACATTTGT AGAGGTTTA CTTGCTTTAA
4201	AAAACCTCCC ACACCTCCCC CTGAACCTGA AACATAAAAT GAATGCAATT
15 4251	GTTGTTGTTA ACTTGTATTAT TGCACTTAT AATGGTTACA AATAAAGCAA
4301	TAGCATCACA AATTTCACAA ATAAAGCATT TTTTTCACTG CATTCTAGTT
4351	GTGGTTTGTC CAAACTCATC AATGTATCTT ATCATGTCTG GATCCTCTAC
20 4401	GCCGGACGCA TCGTGGCCGG CATCACCGGC GCCACAGGTG CGGTTGCTGG
4451	CGCCTATATC GCCGACATCA CCGATGGGGA AGATCGGGCT CGCCACTTCG
25 4501	GGCTCATGAG CGCTTGTPTC GGCGTGGGTA TGGTGGCAGG CCCCCGTGGCC
4551	GGGGGACTGT TGGGCGCCAT CTCCTTGCAT GCACCATTCC TTGCGGGCGGC
4601	GGTGCTCAAC GGCCTCAACC TACTACTGGG CTGCTTCCTA ATGCAGGAGT
30 4651	CGCATAAGGG AGAGCGTCGA GACTCCATCT CAAAAATAAA ATAAAATAAA
4701	AATTAAAAAA AAAGGGCCCT TGTGCAAAGC TGACAGCTTG TATGTTCTG
35 4751	CTGTTGACAT TTGTGGCTG TTTACCAACA CTTCTGGAAC ACAGCAGTGG
4801	AAGGGACTTC CCAGATATTT TAAAATTACC CTTAGAAAGC GGTCTGTGAA
4851	AAACCCCTAC CCAATTTCCT TTTGTTAAG TGACCTAATT AACAGGAGGA
40 4901	CACAGAGGGT GGATGGGAG CCTATGATTG GAATGTCCTC TCAAGTAGAG
4951	GAGGTTAGGG TTTATGAGGA CACAGAGGAG CTTCCCTGGGG ATCCAGACAT
45 5001	GATAAGATAAC ATTGATGAGT TTGGACAAAC CACAACTAGA ATGCAGTGAA
5051	AAAAATGCTT TATTGTGAA ATTGTGATG CTATTGCTTT ATTTGTAACC
5101	ATTATAAGCT GCAATAAACAA AGTTAACAAAC AACAAATTGCA TTCATTTTAT
50 5151	GTTCAGGTT CAGGGGGAGG TGTGGGAGGT TTTTTAAAGC AAGTAAAACC
5201	TCTACAAATG TGGTATGGCT GATTATGATC TCTAGTCAGA GCACTATACA
55 5251	TCAAATATTG CTTATTAACC CCTTTACAAA TTAAAAAGCT AAAGGTACAC
5301	AATTTTGAG CATAGTTATT AATAGCAGAC ACTCTATGCC TGTGTGGAGT
5351	AAGAAAAAAAC AGTATGTTAT GATTATAACT GTTATGCCTA CTTATAAAAGG
60 5401	TTACAGAATA TTTTCCATA ATTTCTTGT ATAGCAGTGC AGCTTTTCC
5451	TTTGTGGTGT AAATAGCAAA GCAAGCAAGA GTTCTATTAC TAAACACAGC

-8-

5501 ATGACTCAAA AAACCTAGCA ATTCTGAAGG AAAGTCCTTG GGGTCTTCTA  
 5551 CCTTTCTCTT CTTTTTTGGA GGAGTAGAAT GTTGAGAGTC AGCAGTAGCC  
 5 5601 TCATCATCAC TAGATGGCAT TTCTTCTGAG CAAAACAGGT TTTCCCTCATT  
 5651 AAAGGCATTC CACCACTGCT CCCATTCACTC AGTTCCATAG GTTGGAAATCT  
 10 5701 AAAATACACA AACAAATTAGA ATCAGTAGTT TAACACATTA TACACTTAAA  
 5751 AATTTTATAT TTACCTTAGA GCTTTAAATC TCTGTAGGTA GTTTGTCCAA  
 5801 TTATGTCACA CCACAGAAGT AAGGTTCCCTT CACAAAGATC TAAAGCCAGC  
 15 5851 AAAAGTCCCCA TGGTCTTATA AAAATGCATA GCTTTAGGAG GGGAGCAGAG  
 5901 AACTTGAAAG CATCTTCCTG TTAGTCTTTC TTCTCGTAGA CTTCAAACATT  
 20 5951 ATACTTGATG CCTTTTTCCCT CCTGGACCTC AGAGAGGACG CCTGGGTATT  
 6001 CTGGGAGAAG TTTATATTTTC CCCAAATCAA TTTCTGGAA AAACGTGTCA  
 6051 CTTTCAAATT CCTGCATGAT CCTTGTACAA AAGAGTCTGA GGTGGCCTGG  
 25 6101 TTGATTCATG GCTTCCTGGT AAACAGAACT GCCTCCGACT ATCCAAACCA  
 6151 TGTCTACTTT ACTTGCCAAT TCCGGTTGTT CAATAAGTCT TAAGGCATCA  
 6201 TCCAAACTTT TGGCAAGAAA ATGAGCTCCT CGTGGTGGTT CTTTGAGTT  
 30 6251 TCTACTGAGA ACTATATTAA TTCTGTCTT TAAAGGTGCA TTCTTCTCAG  
 6301 GAATGGAGAA CCAGGTTTTC CTACCCATAA TCACCCAGATT CTGTTTACCT  
 35 6351 TCCACTGAAG AGGTTGTGGT CATTCTTGG AAGTACTTGA ACTCGTTCC  
 6401 GAGCGGAGGC CAGGGTAGGT CTCCGTTCTT GCCAATCCCC ATATTTGGG  
 40 6451 ACACGGCGAC GATGCAGTTC AATGGTCGAA CCATGATGGC AGCGGGGATA  
 6501 AAATCCTACC AGCCTTCACG CTAGGATTGC CGTCAAGTTT GGCGCGAAAT  
 6551 CGCAGCCCTG AGCTGTCCCC CCCCCCAAGC TTTTTGCAAA AGCCTAGGCC  
 45 6601 TCCAAAAAAAG CCTCCTCACT ACTTCTGGAA TAGCTCAGAG GCCGAGGCC  
 6651 CCTCGGCCTC TGCATAAATA AAAAAAATTA GTCAGCCATG GGGCGGAGAA  
 50 6701 TGGGCGGAAC TGGGCGGAGT TAGGGGGGG ATGGGCGGAG TTAGGGGGGG  
 6751 GACTATGGTT GCTGACTAAT TGAGATGCTG CCTCGCGCGT TTCGGTGATG  
 6801 ACGGTGAAAAA CCTCTGACAC ATGCAGCTCC CGGAGACGGT CACAGCTTGT  
 55 6851 CTGTAAGCGG ATGCCGGAG CAGACAAGCC CGTCAGGGCG CGTCAGCGGG  
 6901 TGTTGGCGGG TGTCGGGCG CAGCCATGAC CCAGTCACGT AGCGATAGCG  
 6951 GAGTGTATAC TGGCTTAAC ATGCGGCATC AGAGCAGATT GTACTGAGAG  
 60 7001 TGCACCATAT GCGGTGTGAA ATACCGCACA GATGCGTAAG GAGAAAATAC  
 7051 CGCATCAGGC GCTCTCCGC TTCTCGCTC ACTGACTCGC TGCAGCTCGGT

7101 CGTTCCGGCTG CGGCGAGCGG TATCAGCTCA CTCAAAGGCG GTAATACGGT  
 7151 TATCCACAGA ATCAGGGGAT AACCGAGGAA AGAACATGTG AGCAAAAGGC  
 5 7201 CAGCAAAAGG CCAGGAACCG TAAAAAGGCC GCGTTGCTGG CGTTTTCCA  
 7251 TAGGCTCCGC CCCCCTGACG AGCATCACAA AAATCGACGC TCAAGTCAGA  
 10 7301 GGTGGCGAAA CCCGACAGGA CTATAAAAGAT ACCAGGCCTT TCCCCCTGGA  
 7351 AGCTCCCTCG TGCGCTCTCC TGTTCCGACC CTGCCGCTTA CCGGATACCT  
 15 7401 GTCCGCCTTT CTCCCTTCGG GAAGCGTGGC GCTTTCTCAT AGCTCACGCT  
 7451 GTAGGTATCT CAGTTCCGTG TAGGTCGTTG GCTCCAAGCT GGGCTGTGTG  
 7501 CACGAACCCC CCGTTCAGCC CGACCGCTGC GCCTTATCCG GTAACATATCG  
 20 7551 TCTTGAGTCC AACCCGGTAA GACACGACTT ATCGCCACTG GCAGCAGCCA  
 7601 CTGGTAACAG GATTAGCAGA GCGAGGTATG TAGGCGGTGC TACAGAGTTG  
 7651 TTGAAGTGGT GGCCTAACTA CGGCTACACT AGAAGGACAG TATTGGTAT  
 25 7701 CTGCGCTCTG CTGAAGCCAG TTACCTTCGG AAAAGAGTT GGTAGCTCTT  
 7751 GATCCGGCAA ACAAAACCACC GCTGGTAGCG GTGGTTTTTT TGTTGCAAG  
 30 7801 CAGCAGATTAA CGCGCAGAAA AAAAGGATCT CAAGAAGATC CTTTGATCTT  
 7851 TTCTACGGGG TCTGACGCTC AGTGGAACGA AAACTCACGT TAAGGGATTT  
 7901 TGGTCATGAG ATTATCAAAA AGGATCTTCA CCTAGATCCT TTTAAATTAA  
 35 7951 AAATGAAGTT TTAAATCAAT CTAAAGTATA TATGAGTAAA CTTGGTCTGA  
 8001 CAGTTACCAA TGCTTAATCA GTGAGGCACC TATCTCAGCG ATCTGTCTAT  
 40 8051 TTCGTTCATC CATAGTTGCC TGACTCCCCG TCGTGTAGAT AACTACGATA  
 8101 CGGGAGGGCT TACCATCTGG CCCCAGTGCT GCAATGATAC CGCGAGACCC  
 45 8151 ACGCTCACCG GCTCCAGATT TATCAGCAAT AAACCAGCCA GCCGGAAGGG  
 8201 CCGAGCGCAG AAGTGGCCT GCAACTTTAT CCGCCTCCAT CCAGTCTATT  
 8251 AATTGTTGCC GGGAAAGCTAG AGTAAGTAGT TCGCCAGTTA ATAGTTTGCG  
 50 8301 CAACGTTGTT GCCATTGCTG CAGGCATCGT GGTGTCACGC TCGTCGTTG  
 8351 GTATGGCTTC ATTCAAGCTCC GGTTCCCAAC GATCAAGGCG AGTTACATGA  
 55 8401 TCCCCCATGT TGTGCAAAAA AGCGGTTAGC TCCTTCGGTC CTCCGATCGT  
 8451 TGTCAGAAGT AAGTGGCCG CAGTGTATAC ACTCATGGTT ATGGCAGCAC  
 8501 TGCATAATTTC TCTTACTGTC ATGCCATCCG TAAGATGCTT TTCTGTGACT  
 60 8551 GGTGAGTACT CAACCAAGTC ATTCTGAGAA TAGTGTATGC GGCGACCGAG  
 8601 TTGCTCTTGC CCGCGTCAA CACGGATAA TACCGCGCCA CATAGCAGAA

-10-

8651	CTTTAAAAGT GCTCATCATT GGAAAACGTT CTTCGGGGCG AAAACTCTCA
8701	AGGATCTTAC CGCTGTTGAG ATCCAGTTCG ATGTAACCCA CTCGTGCACC
5	8751 CAACTGATCT TCAGCATCTT TTACTTTAC CAGCGTTCT GGGTGAGCAA
8801	AAACAGGAAG GCAAAATGCC GCAAAAAAGG GAATAAGGGC GACACGGAAA
10	8851 TGTTGAATAC TCATACTCTT CCTTTTCAA TATTATTGAA GCATTTATCA
8901	GGGTTATTGT CTCATGAGCG GATACATATT TGAATGTATT TAGAAAAATA
8951	AACAAATAGG GGTTCCGCGC ACATTTCCCC GAAAAGTGCC ACCTGACGTC
15	9001 TAAGAAACCA TTATTATCAT GACATTAACC TATAAAAATA GGCGTATCAC
9051	GAGGCCCTT CGTCTTCAAG AATTCCG

Sequence ID #2: Nucleotide sequence of the rabbit TGF $\beta$ RII:Fc

25 ATGGGTCGGGGCTGCTCCGGGCCTGTGGCCGCTGCACCTCGTCTGTGGACGCCATC  
832  
892  
GCCAGCACGATCCGCCGCACGTTAGAAGTCGGTTAATAACGACATGATGGTCACGGAC  
30  
952  
AACAAATGGCGCCGTCAAGTTCCCACAACACTGTGCAAGTTTGCATGTGCGATCTTCACC  
35  
1012  
1072  
TGTGACAACCAGAAGTCCTGCATGAGCAACTGCAGCATCACGTCCATCTGTGAGAAGGCA  
CACGAAGTCTGCGTGGCGTCTGGAGGAAGAACGATGAAAACATAACCCGGAGACTGTG  
40  
1132  
1192  
TGTCAAGACCCAAAGCTCGCCTACCATGGATTCTTCTGGAAGATTCTGCCTCTCCAAAG  
TGTATCATGAAAGAAAAGAAGGTGTTGGGAGACTTCTTCATGTGTTCTGCAGCACT  
45  
1252  
1312  
GACGAGTGCAATGACCACATCATCTCTGTAGGAATACACCACCGAGTCGGATCTG  
GTGACAAAACATCACACATGCCACCGTGCCCAGCACCTGAACTCCTGGGGGACCGTCA  
50  
1372  
1432  
GTCTTCCTCTCCCCCAAAACCCAGGACACCCCTCATGATCTCCGGACCCCTGAGGTC  
ACATGCGTGGTGGACGTGAGCCACGAAGACCCGTAGGTCAAGTTCAACTGGTACGTG  
55  
1492  
1552  
GACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACG  
TACCGTGTGGTCAGCGTCCTCACCGTCTGCACCAGGACTGGCTGAATGGCAAGGAGTAC  
60  
AAGTGCAAGGTCTCCAACAAAGCCCTCCAGCCCCATCGAGAAAACCATCTCCAAAGCC

-11-

1612 AAAGGGCAGCCCCGAGAACCAACAGGTGTACACCCCTGCCCCATCCGGGATGAGCTGACC  
5 1672 AAGAACCAAGGTCAAGCCTGACCTGCCTGGTCAAAGGTTCTATCCCAGCGACATGCCGTG  
10 1732 GAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCCTCCGTGTTGGAC  
1792 TCCGACGGCTCCTTCTTCCTCTACAGCAAGCTACCGTGGACAAGAGCAGGTGGCAGCAG  
1852 15 GGGAACGTCTTCTCATGCTCCGTATGCATGAGGCTCTGCACAACCAACTACACGCAGAAG  
1912 1972 AGCCTCTCCCTGTCTCCGGTAAA

SEQUENCE ID #3: Nucleotide Sequence of the human TGF $\beta$ RII:Fc expression vector

1 GAATTCGAGC TTGCATGCCT GCAGGTCGTT ACATAACTTA CGGTAAATGG  
30 51 CCCGCCTGGC TGACCCGCCA ACGACCCCCG CCCATTGACG TCAATAATGA  
101 CGTATGTTCC CATACTAACG CCAATAGGGA CTTTCCATTG ACGTCAATGG  
151 GTGGAGTATT TACGGTAAAC TGCCCCATTG GCAGTACATC AAGTGTATCA  
35 201 TATGCCAAGT ACGCCCCCTA TTGACGTCAA TGACGGTAAA TGGCCCGCCT  
251 GGCATTATGC CCAGTACATG ACCTTATGGG ACTTTCTTAC TTGGCAGTAC  
301 ATCTACGTAT TAGTCATCGC TATTACCATG GTGATGCCGT TTTGGCAGTA  
40 351 CATCAATGGG CGTGGATAGC GGTTTGACTC ACGGGGATTT CCAAGTCTCC  
401 ACCCCATTGA CGTCAATGGG AGTTTGTGTTT GGCACCAAAA TCAACGGGAC  
45 451 TTTCCAAAAT GTCGTAACAA CTCCGCCCTA TTGACGCAAA TGGGCCGTAG  
501 GCGTGTACGG TGGGAGGTCT ATATAAGCAG AGCTCGTTA GTGAACCGTC  
551 AGATCGCCTG GAGACGCCAT CCACGCTGTT TTGACCTCCA TAGAAGACAC  
601 CGGGACCGAT CCAGCCTCCG GACTCTAGAG GATCCGGTAC TCGAGGAACT  
651 GAAAAACCAAG AAAGTTAACT GGTAAGTTA GTCTTTTGT CTTTTATTTG  
55 701 AGGTCCCGGA TCCGGTGGTG GTGCAAATCA AAGAACTGCT CCTCAGTGGA  
751 TGTTGCCTTT ACTTCTAGGC CTGTACGGAA GTGTTACTTC TGCTCTAAAA  
801 GCTGCGGAAT TGTACCCGCG GCCGCTCTGC CATGGGTCGG GGGCTGCTCA  
60 851 GGGGCCTGTG GCCGCTGCAC ATCGTCCTGT GGACGCGTAT CGCCAGCACG  
901 ATCCCCACCGC ACGTTCAAGAA GTCGGTTAAT AACGACATGA TAGTCACTGA

-12-

	951	CAACAACGGT GCAGTCAAGT TTCCACAACT GTGTAAATT TGTGATGTGA
5	1001	GATTTTCCAC CTGTGACAAC CAGAAATCCT GCATGAGCAA CTGCAGCATC
	1051	ACCTCCATCT GTGAGAACCC ACAGGAAGTC TGTGTGGCTG TATGGAGAAA
10	1101	GAATGACGAG AACATAACAC TAGAGACAGT TTGCCATGAC CCCAAGCTCC
	1151	CCTACCATGA CTTTATTCTG GAAGATGCTG CTTCTCCAAA GTGCATTATG
	1201	AAGGAAAAAA AAAAGCCTGG TGAGACTTTC TTCAATGTGTT CCTGTAGCTC
15	1251	TGATGAGTGC AATGACAACA TCATCTTCTC AGAAGAATAT AACACCAGCA
	1301	ATCCTGACTT GGTCGACAAA ACTCACACAT GCCCACCCTG CCCAGCACCT
	1351	GAACTCCTGG GGGGACCGTC AGTCTTCCTC TTCCCCCAA AACCCAAGGA
20	1401	CACCCCTCATG ATCTCCCGA CCCCTGAGGT CACATGCGTG GTGGTGGACG
	1451	TGAGCCACGA AGACCCCTGAG GTCAAGTTCA ACTGGTACGT GGACGGCGTG
25	1501	GAGGTGCATA ATGCCAAGAC AAAGCCGCGG GAGGAGCAGT ACAACAGCAC
	1551	GTACCGTGTG GTCAGCGTCC TCACCGTCCT GCACCAGGAC TGGCTGAATG
	1601	GCAAGGAGTA CAAGTCCAAG GTCTCCAACA AAGCCCTCCC AGCCCCATC
30	1651	GAGAAAACCA TCTCCAAAGC CAAAGGGCAG CCCCGAGAAC CACAGGTGA
	1701	CACCCCTGCC CCATCCCGGG ATGAGCTGAC CAAGAACCAAG GTCAGCCTGA
35	1751	CCTGCCCTGGT CAAAGGCTTC TATCCCAAGCG ACATGCCGT GGAGTGGAG
	1801	AGCAATGGGC AGCCGGAGAA CAACTACAAG ACCACGCCCTC CCGTGTGGGA
	1851	CTCCGACGGC TCCTTCTTCC TCTACAGCAA GCTCACCGTG GACAAGAGCA
40	1901	GGTGGCAGCA GGGGAACGTC TTCTCATGCT CCGTGTGCA TGAGGCTCTG
	1951	CACAACCAC ACTACGAGAA GAGCCTCTCC CTGTCTCCGG GTAAATGAGT
45	2001	GCggccgcGT CGACCGTGAC CCCCTGCC CGGGACTCC TGCCCCGAGG
	2051	GTCCGGACGC GCCCCAGCTC GCGCCCTTC CCATATTTAT TCGGACCCCA
	2101	AGCATCGCCC CAATAAGAC CAGCAAGCAA CGGGCTGGGG TGTCCGTGCG
50	2151	TGTTAGGGGG CCCGTGGGAC CTCCCTTGCC GTCTCTCCTC GCGCACGGCC
	2201	CGGGTCCGCC CTGTAGCGCT CGCTGTCTCT CCCCTGCCTG AAGGCCCCA
55	2251	CCACCGTCTT TCAGGCCCG GACTTGGTGC CGGGTCCAGG CGTAAAGGAG
	2301	CAGGTGACTC TGCGCAGCAC TCGCTTTATT TCGCCAGAGT CGCGGGCGT
	2351	CCAGAAGGGG CCCCTGGACT CGGGCCGGG GCCGGCTCAG TCCCCCCCCT
60	2401	TGCCTGCGCG GAGCTTCTGG CGACTCCCAG GCGCTGCTC CTCGTGGGA
	2451	CGCCTCGGGG ACACCCAGGC CTGCTTCTTC CTGGGCTCGG CGTCCCTGGGA

-13-

2501	GTCCCGTGCC CACGGCCGGT GGCCCCCTTC GCGTGACTCC CAGCGCTGGG
2551	GTAGGGCTTC CGGGGGCTCC CTGGCGGCCG GTGGCCTCTC CTCTTTCGCG
5	2601 GGCCTCTCTT TCTTAGGTCT CTCCTCCTTC CGCGGCTTCT CCTTCCGCG
2651	CTTCCCCCTCT CTCCGAGGCC TCTCCTTGGG TCCCCGGTCT GCGAGGGTCA
10	2701 CACGGTCCTC CGGACGGCC TCTCCGGTGG CCTCGCCGGG CTCCTCTTCG
2751	TCGTTCTCTG CAGCCTCCCG ACTCCCGGA ATCTTGGTC TGACCTCTGC
15	2801 CTCGGCCCGG GGCGCAGGCG GCGCTGATGG AGGCGCCTGG GCCTCGAACT
2851	TAGGCTGCAA GACAGAGTGG GGTCTCTGGGG TAAGCGCCCA CCTTCCCCC
2901	GGCCCGGGCT CCTTCTTCC TTGGGGATGA AGGTCCAAT GCCC CGGGTC
2951	AGTGGAAAGGA AGCTCTTACC AGGGGCGACG ATGGCTCCCT CGGGGCTGAG
20	3001 CTTGGCGGGGA CCCAGGGCTC GGGCACACGT GCTTGGAGTG CTGCCTCCG
3051	AGGGACGGCG TCTGCAGCGA CAGGGTCGGG ACCCGAGTCA GCTGGGCCGA
25	3101 GGCACGGTCC ACACITGTCCA TCCCTCCCTC ACCCCTAGAG CCCCCCTCCC
3151	TGGACAGTTG GAGTGGGCT CCCCCGGTAC GGCTGAGACT AAGGATGCC
3201	CCGAGCCGTG GGAAGGGACT CGGGGACTCC GCTGCCCGGG CGCCCCCTCT
30	3251 CCGAACCTCG CTCTTCAAT TGGTCATTCT TCCCCCGAC CACGGGCTGT
3301	AGGAGGCCCC TAGCAAGGGA GGGTCGCAG GAGTCCCCC GGGGGCGCT
35	3351 CACGAGCTGA CGGGTCCCCA GAGAGGGCGC AGGGAAAGG CGGCAGAACG
3401	CTACGAGGCA GGAGGGTTG CACAAGGTTT ACACGGAAAGC CAGAACCTAC
3451	TCGCGGGCGAG GGGAAATGGC CCCGCAAAG GTCCACACCG GGTGAGAGGG
40	3501 GCGCGCAAGG CCCGTCActt aaGGGACATA TGACGTGAGC TCAGATCTTT
3551	GTGAAGGAAC CTTACTCTG TGGTGTGACA TAATTGGACA AACTACCTAC
45	3601 AGAGATTTAA AGCTCTAAGG TAAATATAAA ATTTTTAAGT GTATAATGTG
3651	TTAAACTACT GATTCTAATT GTTGTGTAT TTTAGATTCC AACCTATGGA
50	3701 ACTGATGAAT GGGAGCAGTG GTGGAATGCC TTTAATGAGG AAAACCTGTT
3751	TTGCTCAGAA GAAATGCCAT CTAGTGATGA TGAGGCTACT GCTGACTCTC
3801	AACATTCTAC TCCCTCCAAAA AAGAAGAGAA AGGTAGAAGA CCCCCAAGGAC
55	3851 TTTCTTCAG AATTGCTAAG TTTTTTGAGT CATGCTGTGT TTAGTAATAG
3901	AACTCTTGCT TGCTTGCTA TTTACACCAAC AAAGGAAAAA GCTGCACTGC
3951	TATACAAGAA AATTATGGAA AAATATTCTG TAACCTTAT AAGTAGGCAT
60	4001 AACAGTTATA ATCATAAACAT ACTGTTTTTT CTTACTCCAC ACAGGCATAG
4051	AGTGTCTGCT ATTAATAACT ATGCTAAAA ATTGTGTACC TTTAGCTTTT

-14-

4101	TAATTTGTAAGGGGTTAAT AAGGAATATT TGATGTATAG TGCCTTGACT
4151	AGAGATCATA ATCAGCCATA CCACATTTGT AGAGGTTTTA CTTGCTTTAA
5 4201	AAAACCTCCC ACACCTCCCC CTGAACCTGA AACATAAAAT GAATGCAATT
4251	GTTGTTGTTA ACTTGTGTTAT TGCAGCTTAT AATGGTTACA AATAAAGCAA
10 4301	TAGCATCACAA AATTTCACAA ATAAAGCATT TTTTCACtg CATTCTAGTT
4351	GTGGTTTGTC CAAACTCATC AATGTATCTT ATCATGTCTG GATCCTCTAC
15 4401	GCCGGACGCA TCGTGGCCGG CATCACCGGC GCCACAGGTG CGGTTGCTGG
4451	CGCCTATATTC GCCGACATCA CCGATGGGGA AGATCGGGCT CGCCACTTCG
4501	GGCTCATGAG CGCTTGTGTTG GGCCTGGGTA TGGTGGCAGG CCCCCTGGCC
20 4551	GGGGGACTGT TGGGCGCCAT CTCCTTGCAT GCACCATTCC TTGCGGCCGGC
4601	GGTGCTCAAC GGCCTCAACC TACTACTGGG CTGCTTCCTA ATGCAGGAGT
4651	CCGCATAAGGG AGAGCGTCGA GACTCCATCT CAAAAATAAA ATAAAATAAA
25 4701	AATTAAAAAA AAAGGGCCCT TGTGCAAAGC TGACAGCTTG TATGTTCTG
4751	CTGTTGACAT TTGTGGGCTG TTTACCAACA CTTCTGGAAC ACAGCAGTGG
30 4801	AAGGGACTTC CCAGATATTT TAAAATTACC CTTAGAAAGC GGTCTGTGAA
4851	AAACCCCTAC CCAATTTCCT TTTTGTAAAG TGACCTAATT AACAGGAGGA
4901	CACAGAGGGT GGATGGCAG CCTATGATTG GAATGTCCTC TCAAGTAGAG
35 4951	GAGGTTAGGG TTTATGAGGA CACAGAGGAG CTTCCCTGGGG ATCCAGACAT
5001	GATAAGATAC ATTGATGAGT TTGGACAAAC CACAACCTAGA ATGCAGTGAA
40 5051	AAAAATGCTT TATTGTGAA ATTGTGATG CTATTGCTTT ATTGTAAACC
5101	ATTATAAGCT GCAATAAACAA AGTTAACAAAC AACAAATTGCA TTCATTATAT
45 5151	GTTCAGGTT CAGGGGGAGG TGTGGGAGGT TTTTTAAAGC AAGTAAAACC
5201	TCTACAAATG TGGTATGGCT GATTATGATC TCTAGTCAG GCACATACAC
5251	TCAAATATTC CTTATTAACC CCTTTACAAA TTAAAAAGCT AAAGGTACAC
50 5301	AATTTTGAG CATAGTTATT AATAGCAGAC ACTCTATGCC TGTGTGGAGT
5351	AAGAAAAAAAC AGTATGTTAT GATTATAACT GTTATGCCTA CTTATAAAGG
5401	TTACAGAATA TTTTCCATA ATTTCCTTGT ATAGCAGTGC AGCTTTTCC
55 5451	TTTGTGGTGT AAATAGCAAA GCAAGCAAGA GTTCTATTAC TAAACACAGC
5501	ATGACTCAAA AAACCTAGCA ATTCTGAAGG AAAGTCCTTG GGGTCTTCTA
60 5551	CCTTTCTCTT CTTTTTGGA GGAGTAGAAT GTTGAGAGTC AGCAGTAGCC
5601	TCATCATCAC TAGATGGCAT TTCTTCTGAG CAAAACAGGT TTTCCCTCATT

-15-

5651 AAAGGCATTC CACCACTGCT CCCATTCATC AGTTCCATAG GTTGGAAATCT  
 5701 AAAATACACA AACAAATTAGA ATCAGTAGTT TAACACATTA TACACTTAAA  
 5 5751 AATTTTATAT TTACCTTAGA GCTTTAAATC TCTGTAGGTA GTTTGTCCAA  
 5801 TTATGTCACA CCACAGAAGT AAGGTTCCCTT CACAAAGATC TAAAGCCAGC  
 5851 AAAAGTCCC A TGGTCTTATA AAAATGCATA GCTTTAGGAG GGGAGCAGAG  
 10 5901 AACTTGAAAG CATCTTCCTG TTAGTCTTTC TTCTCGTAGA CTTCAAACCTT  
 5951 ATACTTGATG CCTTTTTCCCT CCTGGACCTC AGAGAGGACG CCTGGGTATT  
 15 6001 CTGGGAGAAG TTTATATTTT CCAAATCAA TTTCTGGGAA AAACGTGTCA  
 6051 CTTTCAAATT CCTGCATGAT CCTTGTACA AAGAGTCTGA GGTGGCCTGG  
 20 6101 TTGATTTCATG GCTTCCTGGT AAACAGAACT GCCTCCGACT ATCCAAACCA  
 6151 TGTCTACTTT ACTTGCCAAT TCCGGTTGTT CAATAAGTCT TAAGGCATCA  
 6201 TCCAAACTTT TGGCAAGAAA ATGAGCTCCT CGTGGTGGTT CTTTGAGTTC  
 25 6251 TCTACTGAGA ACTATATTAA TTCTGTCCCTT TAAAGGTGCA TTCTTCTCAG  
 6301 GAATGGAGAA CCAGGTTTC CTACCCATAA TCACCAGATT CTGTTTACCT  
 30 6351 TCCACTGAAG AGGTTGTGGT CATTCTTGG AAGTACTTGAA ACTCGTTCC  
 6401 GAGCGGAGGC CAGGGTAGGT CTCCGTTCTT GCCAATCCCC ATATTTGGG  
 6451 ACACGGCGAC GATGCAGTTC AATGGTCGAA CCATGATGGC AGCGGGGATA  
 35 6501 AAATCCTTACCG AGCCTTCACG CTAGGATTGC CGTCAAGTTT GGCGCGAAAT  
 6551 CGCAGCCCTG AGCTGTCCCC CCCCCCAAGC TTTTGCAAA AGCCTAGGCC  
 40 6601 TCCAAAAAAAG CCTCCTCACT ACTTCTGGAA TAGCTCAGAG GCCGAGGCGG  
 6651 CCTCGGCCTC TGCATAAATA AAAAAAAATTAA GTCAGCCATG GGGCGGAGAA  
 6701 TGGGCGGAAC TGGGCGGAGT TAGGGGCGGG ATGGGCGGAG TTAGGGGCGG  
 45 6751 GACTATGGTT GCTGACTAAT TGAGATGCTG CCTCGCGCGT TTGGGTGATG  
 6801 ACGGTGAAAA CCTCTGACAC ATGCAGCTCC CGGAGACGGT CACAGCTTGT  
 50 6851 CTGTAAGCGG ATGCCGGGAG CAGACAAGCC CGTCAGGGCG CGTCAGCGGG  
 6901 TGTTGGCGGG TGTCGGGCG CAGCCATGAC CCAGTCACGT AGCGATAGCG  
 6951 GAGTGTATAC TGGCTTAACT ATGCCGCATC AGAGCAGATT GTACTGAGAG  
 55 7001 TGCACCATAT GCGGTGTGAA ATACCGCACA GATGCGTAAG GAGAAAATAC  
 7051 CGCATCAGGC GCTCTTCCGC TTCTCGCTC ACTGACTCGC TGCCTCGGT  
 7101 CGTTCGGCTG CGGCGAGCGG TATCAGCTCA CTCAAAGGGCG GTAATACGGT  
 60 7151 TATCCACAGA ATCAGGGGAT AACGCAGGAA AGAACATGTG AGCAAAAGGC  
 7201 CAGCAAAAGG CCAGGAACCG TAAAAAGGCC GCGTTGCTGG CGTTTTCCA

-16-

5	7251	TAGGCTCCGC CCCCTGACG AGCATCACAA AAATCGACGC TCAAGTCAGA
	7301	GGTGGCGAAA CCCGACAGGA CTATAAAGAT ACCAGGCGTT TCCCCCTGGA
10	7351	AGCTCCCTCG TGCCTCTCC TGTTCCGACC CTGCCGCTTA CCGGATACCT
	7401	GTCCGCGTTT CTCCCTCGG GAAGCGTGGC GCTTTCTCAT AGCTCACGCT
15	7451	GTAGGTATCT CAGTTCGGTG TAGGTCGTTG GCTCCAAGCT GGGCTGTGTG
	7501	CACGAACCCC CCGTTCAGCC CGACCGCTGC GCCTTATCCG GTAACATATCG
20	7551	TCTTGAGTCC AACCCGGTAA GACACGACTT ATCGCCACTG GCAGCAGCCA
	7601	CTGGTAACAG GATTAGCAGA GCGAGGTATG TAGGCGGTGC TACAGAGTTTC
25	7651	TTGAAGTGGT GGCCTAACTA CGGCTACACT AGAAGGACAG TATTGGTAT
	7701	CTGCGCTCTG CTGAAGCCAG TTACCTTCGG AAAAAGAGTT GGTAGCTCTT
30	7751	GATCCGGCAA ACAAAACCACC GCTGGTAGCG GTGGTTTTTT TGTTTGCAAG
	7801	CAGCAGATTA CGCGCAGAAA AAAAGGATCT CAAGAAGATC CTTGATCTT
35	7851	TTCTACGGGG TCTGACGCTC AGTGGAACGA AAAACTCACGT TAAGGGATTT
	7901	TGGTCATGAG ATTATCAAAA AGGATCTTCA CCTAGATCCT TTTAAATTAA
40	7951	AAATGAAGTT TAAATCAAT CTAAGTATA TATGAGTAAA CTTGGTCTGA
	8001	CAGTTACCAA TGCTTAATCA GTGAGGCACC TATCTCAGCG ATCTGTCTAT
45	8051	TTCGTTCATC CATACTTGCC TGACTCCCCG TCGTGTAGAT AACTACGATA
	8101	CGGGAGGGCT TACCATCTGG CCCCAGTGCT GCAATGATAC CGCGAGACCC
	8151	ACGCTCACCG GCTCCAGATT TATCAGCAAT AAACCAGCCA GCCGGAAGGG
50	8201	CCGAGCGCAG AAGTGGCCT GCAACTTTAT CCGCCTCCAT CCAGTCTATT
	8251	AATTGTTGCC GGGAAAGCTAG AGTAAGTAGT TCGCCAGTTA ATAGTTTGCG
55	8301	CAACGTTGTT GCCATTGCTG CAGGCATCGT GGTGTCACGC TCGTCGTTG
	8351	GTATGGCTTC ATTCAAGCTCC GGTTCCCAAC GATCAAGGCG AGTTACATGA
60	8401	TCCCCCATGT TGTGCAAAAA AGCGGTTAGC TCCTTCGGTC CTCCGATCGT
	8451	TGTCAGAAGT AAGTTGGCCG CAGTGTATC ACTCATGGTT ATGGCAGCAC
	8501	TGCATAATTC TCTTACTGTC ATGCCATCCG TAAGATGCTT TTCTGTGACT
	8551	GGTGAGTACT CAACCAAGTC ATTCTGAGAA TAGTGTATGC GGCAGCGAG
	8601	TTGCTCTTGC CCGGCGTCAA CACGGGATAA TACCGGCCA CATAGCAGAA
	8651	CTTTAAAAGT GCTCATCATT GGAAACGTT CTTCGGGGCG AAAACTCTCA
	8701	AGGATCTTAC CGCTGTTGAG ATCCAGTTCG ATGTAACCCA CTCGTGCACC
	8751	CAACTGATCT TCAGCATCTT TTACTTTCAC CAGCGTTTCT GGGTGAGCAA

-17-

8801 AACAGGAAG GCAAAATGCC GCAAAAAGG GAATAAGGC GACACGGAAA  
 8851 TGTGAATAC TCATACTCTT CCTTTTCAA TATTATTGAA GCATTATCA  
 5 8901 GGGTTATTGT CTCATGAGCG GATACATATT TGAATGTATT TAGAAAATA  
 8951 AACAAATAGG GGTTCCGCGC ACATTTCCCC GAAAAGTGCC ACCTGACGTC  
 10 9001 TAAGAAACCA TTATTATCAT GACATTAACC TATAAAAATA GGCGTATCAC  
 9051 GAGGCCCTTT CGTCTTCAAG AATTCCG

15       SEQUENCE ID# 4: Nucleotide sequence of human TGF $\beta$ RII:Fc  
 ATGGGTGGGGCTGCTCAGGGCCTGTGGCGCTGCACATCGCCTGTGGACGCGTATC  
 832  
 20       GCCAGCACGATCCCACCGCACGTTAGAACGTCGTTAACGACATGATAGTCAGTGCAC  
 892  
 25       AACAAACGGTGCAGTCAAGTTCCACAACGTGTAATTGTGATGTGAGATTTCCACC  
 952  
 25       TGTGACAACCAGAAATCCTGCATGAGCACTGCAGCATCACCTCCATCTGTGAGAACCCA  
 1012  
 30       CAGGAAGTCTGTGTGGCTGTATGGAGAAAGAACATGACGAGAACATAACACTAGAGACAGTT  
 1072  
 35       TGCCATGACCCCAAGCTCCCTACCATGACTTTATTCTGGAAGATGCTGCTCTCCAAAG  
 1132  
 35       TGCATTATGAAGGAAAAAGCCTGGTGAGACTTCTTCATGTGTTCTGTAGCTCT  
 1192  
 40       GATGAGTGCAATGACAACATCATCTCTCAGAAGAATATAACACCAGCAATCCTGACTTG  
 1252  
 40       GTCGACAAAACTCACACATGCCACCGTGCCAGCACCTGAACCTCTGGGGGACCGTCA  
 1312  
 45       GTCTTCTCTCCCCCAAAACCAAGGACACCCCTCATGATCTCCGGACCCCTGAGGTC  
 1372  
 45       ACATGCGTGGTGGTGACGTGAGCCACGAAGACCCCTGAGGTCAAGTTCACTGGTACGTG  
 1432  
 50       GACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGGGAGGAGCAGTACAACAGCACG  
 1492  
 55       TACCGTGTGGTCAGCGCCTCACCGTCTGCACCAGGACTGGCTGAATGGCAAGGAGTAC  
 1552  
 55       AAAGTGCAGGTCTCCAACAAAGCCCTCCAGCCCCATCGAGAAAACCATCTCCAAAGCC  
 1612  
 60       AAAGGGCAGCCCCGAGAACCAACAGGTGTACACCCCTGCCCCCATCCGGGATGAGCTGACC  
 1672  
 60       AAGAACCCAGGTCAAGCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATGCCGTG  
 1732

-18-

47  
1-3

1792 GAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCCTCCCGTGTGGAC  
 5 TCCGACGGCTCCCTCTTCCTCTACAGCAAGCTACCGTGGACAAGAGCAGGTGGCAGCAG  
 1852 GGGAACGTCTCTCATGCTCCGTATGCATGAGGCTCTGCACAACCACTACACGCAGAAG  
 10 1912 AGCCTCTCCCTGTCCTCCGGTAAAT  
 1972

15 SEQUENCE ID #5: Forward Primer - Rabbit and Human  
 5' - AAGGAAAAAAAGCGGCCGCTCTGCCATGGGTCGGGGCTG - 3'  
 20 SEQUENCE ID #6: Reverse Primer - Rabbit  
 5' - AGTTTTGTCGACCAGATCCGGACTGCTGGGTGGT - 3'  
 25  
 30 SEQUENCE ID #7: Reverse Primer - Human  
 5' - AGTTTTGTCGACCAAGTCAGGATTGCTGGTGTAA - 3'  
 35 Sequence ID #8: Amino acid sequence of the rabbit TGF $\beta$ RII:Fc  
 1 M G R G L L R G L W P L H L V L W T R I  
 A S T I P P H V Q K S V N N D M M M V T D  
 40 N N G A V K F P Q L C K F C D V R S S T  
 C D N Q K S C M S N C S I T S I C E K A  
 45 H E V C V A V W R K N D E N I T L E T V  
 C H D P K L A Y H G F L L E D S A S P K  
 50 C I M K E K K V F G E T F F M C S C S T  
 D E C N D H I I F S E E Y T T S S P D L  
 55 V D K T H T C P P C P A P E L L G G P S  
 161  
 60 V F L F P P K P K D T L M I S R T P E V

-19-

T C V V V D V S H E D P E V K F N W Y V  
 5 D G V E V H N A K T K P R E E Q Y N S T  
 Y R V V S V L T V L H Q D W L N G K E Y  
 10 K C K V S N K A L P A P I E K T I S K A  
 K G Q P R E P Q V Y T L P P S R D E L T  
 15 K N Q V S L T C L V K G F Y P S D I A V  
 E W E S N G Q P E N N Y K T T P P V L D  
 20 S D G S F F L Y S K L T V D K S R W Q Q  
 G N V F S C S V M H E A L H N H Y T Q K  
 25 S L S L S P G K  
 30

SEQUENCE ID# 9: Amino acid sequence of human TGF $\beta$ RII:Fc

35 M G R G L L R G L W P L H I V L W T R I  
 1 A S T I P P H V Q K S V N N D M I V T D  
 40 N N G A V K F P Q L C K F C D V R F S T  
 C D N Q K S C M S N C S I T S I C E K P  
 45 Q E V C V A V W R K N D E N I T L E T V  
 C H D P K L P Y H D F I L E D A A S P K  
 C I M K E K K K P G E T F F M C S C S S  
 55 D E C N D N I I F S E E Y N T S N P D L  
 V D K T H T C P P C P A P E L L G G P S  
 161 V F L F P P K P K D T L M I S R T P E V

-20-

T C V V V D V S H E D P E V K F N W Y V  
5 D G V E V H N A K T K P R E E Q Y N S T  
Y R V V S V L T V L H Q D W L N G K E Y  
10 K C K V S N K A L P A P I E K T I S K A  
K G Q P R E P Q V Y T L P P S R D E L T  
15 K N Q V S L T C L V K G F Y P S D I A V  
E W E S N G Q P E N N Y K T T P P V L D  
S D G S F F L Y S K L T V D K S R W Q Q  
25 G N V F S C S V M H E A L H N H Y T Q K  
S L S L S P G K  
30

Sequence ID No. 10: Rabbit RII:Fc fusion "Junction" nucleotide sequence  
35 TCTGAGGAATACACCACCAGCAGTCCGGATCTGGTCGACAAAACTCACACATGCCAACCGTGCCCA

40 SEQ ID NO: 11 Rabbit RII:Fc fusion "Junction" amino acid sequence  
S E E Y T T S S P D L V D K T H T C P P C P  
45

50 Sequence ID No. 12: Human RII:Fc fusion "Junction" nucleotide sequence  
TCTCAGAAGAATATAACACCAGCAATCCTGACTTGGTCGACAAAACTCACACATGCCAACCGTGC  
55 CCA

55 Sequence ID No. 13: Human RII:Fc fusion "Junction" amino acid sequence  
60 S E E Y N T S N P D L V D K T H T C P P C P

DETAILED DESCRIPTION

The following terms are used herein:

Definitions

"Recombinant," as used herein, means that a protein is derived from recombinant (e.g., 5 microbial or mammalian) expression systems. "Microbial" refers to recombinant proteins made in bacterial or fungal (e.g., yeast) expression systems. As a product, "recombinant microbial" defines a protein produced in a microbial expression system which is essentially free of native endogenous substances. Protein expressed in most bacterial cultures, e.g., *E. coli*, will be free of glycan. Protein expressed in yeast may have a glycosylation pattern different from that 10 expressed in mammalian cells.

"Biologically active," as used throughout the specification as a characteristic of TGF-beta receptors, means that a particular molecule shares sufficient amino acid sequence 15 homology with the embodiments of the present invention disclosed herein to be capable of binding detectable quantities of TGF-beta and/or transmitting a TGF-beta stimulus to a cell, for example, as a component of a hybrid receptor construct, or cross-reacting with anti-TGF-beta receptor antibodies raised against TGF-beta receptor from natural (i.e., nonrecombinant) sources. Preferably, biologically active TGF-beta receptor fusions within the scope of the present invention are capable of binding greater than 0.1 nmoles TGF-beta per nmole receptor, and most preferably, greater than 0.5 nmole TGF-beta per nmole receptor in standard binding 20 assays (see below).

Similarly, a "TGF-beta binding molecule", as used herein, is any molecule exhibiting the same, or substantially the same, biological activity as a TGF-beta receptor fusion protein.

"Individual" means a living organism, including humans, other mammals and any other animals which produce TGF- beta .

"TGF- beta overproduction" as used herein is an amount of TGF- beta present in serum 25 or tissue which is significantly above the normal level. More preferably, TGF-beta overproduction is a level between about 2 and about 20 times normal. Even more preferably, TGF- beta overproduction is a level between about 2 and about 15 times normal. For example, Deguchi measured 24-hour TGF- beta production of bronchoalveolar cells and reported normal 30 levels of  $410 \pm 225 \text{ pg}/10^7 \text{ cells}$  against excess TGF- beta production of  $1288 \pm 453 \text{ pg}/10^7 \text{ cells}$  in systemic lupus erythematosus and  $1417 \pm 471 \text{ pg}/10^7 \text{ cells}$  in scleroderma ((1992) Ann. Rheum. Dis. 51:362-65). TGF- beta overproduction can be determined, in combination with normal levels, by

-22-

measurement of the TGF- beta protein, of TGF- beta mRNA, or of products whose synthesis is stimulated by TGF- beta , such as collagen.

"Connective tissue" is fibrous tissue characterized by the presence of fibroblasts and fibrous proteins such as collagen and elastin.

5 A "fibroproliferative disorder" is characterized by proliferation of fibroblasts plus the corresponding overexpression of extracellular matrix such as fibronectin, laminin and collagen.

A "therapeutic composition" as used herein is defined as comprising the proteins of the invention and other physiologically compatible ingredients. The therapeutic composition may contain excipients such as water, minerals and carriers such as protein.

10 "A sufficient amount" of the proteins of the invention as used herein refers to the amount of TGF- beta receptor fusion protein that neutralizes the biologic activity of excess TGF- beta . It may be determined by (1) suitable clinical variables of improvement, (2) pathologic evaluation of the effects on fibrosis and/or immunosuppression or prevention of fibrosis, or (3) a direct inhibition of TGF- beta .

15 "amino acid"- a monomeric unit of a peptide, polypeptide, or protein. There are twenty amino acids found in naturally occurring peptides, polypeptides and proteins, all of which are L-isomers. The term also includes analogs of the amino acids and D-isomers of the protein amino acids and their analogs.

20 "protein"- any polymer consisting essentially of any of the 20 amino acids. Although "polypeptide" is often used in reference to relatively large polypeptides, and "peptide" is often used in reference to small polypeptides, usage of these terms in the art overlaps and is varied. The term "protein" as used herein refers to peptides, proteins and polypeptides, unless otherwise noted.

25 "functional equivalent" of an amino acid residue is an amino acid having similar physico-chemical properties as the amino acid residue that was replaced by the functional equivalent.

"fusion"- refers to a co-linear, covalent linkage of two or more proteins or fragments thereof via their individual peptide backbones, most preferably through genetic expression of a polynucleotide molecule encoding those proteins.

30 "mutant" - any change in the genetic material of an organism, in particular any change (i.e., deletion, substitution, addition, or alteration) in a wild-type polynucleotide sequence or any change in a wild-type protein.

-23-

"wild-type" - the naturally-occurring polynucleotide sequence of an exon of a protein, or a portion thereof, or protein sequence, or portion thereof, respectively, as it normally exists *in vivo*.

"standard hybridization conditions"- salt and temperature conditions substantially equivalent to 0.5 X SSC to about 5 X SSC and 65 ° C for both hybridization and wash. The term "standard hybridization conditions" as used herein is therefore an operational definition and encompasses a range of hybridization conditions. Higher stringency conditions may, for example, include hybridizing with plaque screen buffer (0.2% polyvinylpyrrolidone, 0.2% Ficoll 400; 0.2% bovine serum albumin, 50 mM Tris-HCl (pH 7.5); 1 M NaCl; 0.1% sodium pyrophosphate; 1 % SDS); 10% dextran sulphate, and 100 µg/ml denatured, sonicated salmon sperm DNA at 65 ° C for 12-20 hours, and washing with 75 mM NaCl/7.5 mM sodium citrate (0.5 x SSC)/1% SDS at 65° C. Lower stringency conditions may, for example, include hybridizing with plaque screen buffer, 10% dextran sulphate and 110 µg/ml denatured, sonicated salmon sperm DNA at 55 ° C for 12-20 hours, and washing with 300 mM NaCl/30mM sodium citrate (2.0 X SSC)/1% SDS at 55 ° C. See also **Current Protocols in Molecular Biology**, John Wiley & Sons, Inc. New York, Sections 6.3.1-6.3.6, (1989).

"expression control sequence"- a sequence of polynucleotides that controls and regulates expression of genes when operatively linked to those genes.

"operatively linked"- a polynucleotide sequence (DNA, RNA) is operatively linked to an expression control sequence when the expression control sequence controls and regulates the transcription and translation of that polynucleotide sequence. The term "operatively linked" includes having an appropriate start signal (e.g., ATG) in front of the polynucleotide sequence to be expressed and maintaining the correct reading frame to permit expression of the polynucleotide sequence under the control of the expression control sequence and production of the desired polypeptide encoded by the polynucleotide sequence.

"expression vector"- a polynucleotide, such as a DNA plasmid or phage (among other common examples) which allows expression of at least one gene when the expression vector is introduced into a host cell. The vector may, or may not, be able to replicate in a cell.

"Isolated" (used interchangeably with "substantially pure")- when applied to nucleic acid i.e., polynucleotide sequences, that encode polypeptides, means an RNA or DNA polynucleotide, portion of genomic polynucleotide, cDNA or synthetic polynucleotide which, by virtue of its origin or manipulation: (i) is not associated with all of a polynucleotide with

which it is associated in nature (e.g., is present in a host cell as an expression vector, or a portion thereof); or (ii) is linked to a nucleic acid or other chemical moiety other than that to which it is linked in nature; or (iii) does not occur in nature. By "isolated" it is further meant a polynucleotide sequence that is: (i) amplified *in vitro* by, for example, polymerase chain reaction (PCR); (ii) chemically synthesized; (iii) recombinantly produced by cloning; or (iv) purified, as by cleavage and gel separation.

Thus, "substantially pure nucleic acid" is a nucleic acid which is not immediately contiguous with one or both of the coding sequences with which it is normally contiguous in the naturally occurring genome of the organism from which the nucleic acid is derived.

10 Substantially pure DNA also includes a recombinant DNA which is part of a hybrid gene encoding additional sequences.

15 "Isolated" (used interchangeably with "substantially pure")- when applied to polypeptides means a polypeptide or a portion thereof which, by virtue of its origin or manipulation: (i) is present in a host cell as the expression product of a portion of an expression vector; or (ii) is linked to a protein or other chemical moiety other than that to which it is linked in nature; or (iii) does not occur in nature. By "isolated" it is further meant a protein that is : (i) chemically synthesized; or (ii) expressed in a host cell and purified away from associated proteins. The term generally means a polypeptide that has been separated from other proteins and nucleic acids with which it naturally occurs. Preferably, the polypeptide is also separated 20 from substances such as antibodies or gel matrices (polyacrylamide) which are used to purify it.

25 "heterologous promoter"- as used herein is a promoter which is not naturally associated with a gene or a purified nucleic acid.

30 "Homologous" - as used herein is synonymous with the term "identity" and refers to the sequence similarity between two polypeptides, molecules or between two nucleic acids.

25 When a position in both of the two compared sequences is occupied by the same base or amino acid monomer subunit (for instance, if a position in each of the two DNA molecules is occupied by adenine, or a position in each of two polypeptides is occupied by a lysine), then the respective molecules are homologous at that position. The percentage homology between two sequences is a function of the number of matching or homologous positions shared by the two 30 sequences divided by the number of positions compared x 100. For instance, if 6 of 10 of the positions in two sequences are matched or are homologous, then the two sequences are 60% homologous. By way of example, the DNA sequences CTGACT and CAGGTT share 50%

-25-

homology (3 of the 6 total positions are matched). Generally, a comparison is made when two sequences are aligned to give maximum homology. Examples of references to DEFINE??

The terms "peptide(s)", "protein(s)" and "polypeptide(s)" are used interchangeably herein. The terms "polynucleotide sequence" and "nucleotide sequence" are also used  
5 interchangeably herein.

Practice of the present invention will employ, unless indicated otherwise, conventional techniques of cell biology, cell culture, molecular biology, microbiology, recombinant DNA, protein chemistry, and immunology, which are within the skill of the art. Such techniques are  
10 described in the literature. See, for example, **Molecular Cloning: A Laboratory Manual**, 2nd edition. (Sambrook, Fritsch and Maniatis, eds.), Cold Spring Harbor Laboratory Press, 1989; **DNA Cloning, Volumes I and II** (D.N. Glover, ed), 1985; **Oligonucleotide Synthesis**, (M.J. Gait, ed.), 1984; U.S. Patent No. 4,683,195 (Mullis et al.); **Nucleic Acid Hybridization** (B.D. Hames and S.J. Higgins, eds.), 1984; **Transcription and Translation** (B.D. Hames and S.J.  
15 Higgins, eds.), 1984; **Culture of Animal Cells** (R.I. Freshney, ed). Alan R. Liss, Inc., 1987; **Immobilized Cells and Enzymes**, IRL Press, 1986; **A Practical Guide to Molecular Cloning** (B. Perbal), 1984; **Methods in Enzymology**, Volumes 154 and 155 (Wu et al., eds), Academic Press, New York; **Gene Transfer Vectors for Mammalian Cells** (J.H. Miller and M.P. Calos, eds.), 1987, Cold Spring Harbor Laboratory; **Immunochemical Methods in Cell and**  
20 **Molecular Biology** (Mayer and Walker, eds.), Academic Press, London, 1987; **Handbook of Experiment Immunology**, Volumes I-IV (D.M. Weir and C.C. Blackwell, eds.), 1986; **Manipulating the Mouse Embryo**, Cold Spring Harbor Laboratory Press, 1986.

## II. General Properties of Isolated Proteins and Polynucleotides

### 25 A. Soluble TGF-beta receptor fusions and their Analogs as TGF-beta antagonists

The present invention utilizes isolated and purified TGF-beta antagonist polypeptides. The isolated and purified TGF-beta antagonist polypeptides used in this invention are substantially free of other contaminating materials of natural or endogenous origin and contain less than about 1% by mass of protein contaminants residual of production processes. The  
30 TGF-beta antagonist polypeptides used in this invention are optionally without associated native-pattern glycosylation.

As used herein, the term "TGF-beta receptor" refers to proteins having amino acid sequences which are substantially similar to native mammalian TGF-beta receptor or TGF-beta binding molecule sequences, and which are capable of binding TGF-beta and inhibiting TGF-beta from binding to cell membranes containing TGF-beta receptor. The preferred TGF-beta receptor is mature full-length TGF-beta receptor Type II. TGF- beta receptor Type II is a membrane-bound protein with an intracellular domain, transmembrane domain and extracellular portion which binds to TGF- beta Human TGF- beta receptor Type II has been determined to have the amino acid sequence shown in Lin et al., Cell: 68, 775-785 (1992), and corrected as shown in U.S. Patent 5,693,607.

10 The preferred TGF-beta receptors of the present invention are soluble forms of TGF-beta receptor Type II, as well as soluble TGF-beta Type II binding molecules. Soluble TGF-beta receptors include, for example, analogs or subunits of native proteins having at least 20 amino acids and which exhibit at least some biological activity in common with TGF-beta receptor Type II or TGF-beta binding molecules.

15 The terms "TGF-beta Type II receptor fusion protein" or "TGF-beta RII:Fc" are used interchangeably and represent the most preferred embodiments of the compositions of the present invention. This fusion protein contains at least part of the TGF-beta receptor (Type II) linked to at least part of a second protein that is not TGF-beta receptor Type II. Specifically, the second protein may be the constant region of an immunoglobulin (preferably IgG, most 20 preferably IgG1) or may be a portion thereof such as the hinge, C<sub>H</sub>2 or C<sub>H</sub>3. The preferred fusions of the invention are homodimers, connected to each other by disulfide linkages but heterodimeric forms are also means to be within the scope of the invention. See Section IV.

25 Thus, the most preferred compositions of the present invention are TGF-beta antagonists that are soluble fusion proteins such as recombinant chimeric antibody molecules having TGF-beta receptor sequences substituted for the variable domains of either or both of the immunoglobulin molecule heavy and light chains and having unmodified constant region domains. For example, chimeric TGF-beta RII/IgG1 is produced from a chimeric genes: a TGF-beta RII/human gamma 1 heavy chain chimera. Following transcription and translation of the chimeric gene, the gene product assembles into a homodimer having TGF-beta receptor 30 displayed bivalently. Such polyvalent forms of TGF-beta receptor may have enhanced binding affinity for TGF-beta ligand.

The soluble TGF-beta receptor constructs of the invention are devoid of a transmembrane region (and are secreted from the cell) but retain the ability to bind TGF-beta.

Various bioequivalent protein and amino acid analogs have an amino acid sequence corresponding to all or part of the extracellular region of a native TGF-beta receptor (e.g. SEQ ID NO: 8 or 9) or amino acid sequences substantially similar or are at least 60% homologous to the sequences of SEQ ID NO: 8 or 9 and which are biologically active in that they bind to 5 TGF-beta ligand. Equivalent TGF-beta receptors include polypeptides which vary from these sequences by one or more substitutions, deletions, or additions, and which retain the ability to bind TGF-beta or inhibit TGF-beta signal transduction activity via cell surface bound TGF-beta receptor proteins. Inhibition of TGF-beta signal transduction activity can be determined by 10 transfecting cells with recombinant TGF-beta receptor DNAs to obtain recombinant receptor expression. The cells are then contacted with TGF-beta and the resulting metabolic effects examined. If an effect results which is attributable to the action of the ligand, then the 15 recombinant receptor has signal transduction activity. Exemplary procedures for determining whether a polypeptide has signal transduction activity are disclosed by Idzerda et al., J. Exp. Med. 171:861 (1990); Curtis et al., Proc. Natl. Acad. Sci. U.S.A. 86:3045 (1989); Prywes et al., EMBO J. 5:2179 (1986) and Chou et al., J. Biol. Chem. 262:1842 (1987). Alternatively, 20 primary cells or cell lines which express an endogenous TGF-beta receptor and have a detectable biological response to TGF-beta could also be utilized.

A "fragment" of the proteins of this invention is a portion or all of a protein which is 25 capable of binding TGF- beta. Preferably, this fragment has a high affinity for TGF- beta. Preferred fragments of fusion proteins are protein fragments comprising at least part of the extracellular portion of the TGF- beta receptor Type II bound to at least part of a constant region of an immunoglobulin . Preferably, the affinity is in the range of about  $10^{-11}$  to  $10^{-12}$  M, although the affinity may vary considerably with fragments of different sizes, ranging from  $10^{-7}$  to  $10^{-13}$  M. In one embodiment, the fragment is about 10-110 amino acids in length and 30 comprises the TGF- beta binding site linked to at least part of a constant region of an immunoglobulin.

If the native amino acid sequence of the extracellular domain of TGF-beta receptor (e.g. amino acids 1 to 160 of SEQ ID NOS: 8 or 9) is used in the fusion proteins, the amino acid sequence resembles that of the entire extracellular portion of the Type II receptor. When smaller 35 TGF beta -receptor Type II portions are employed, they resemble various portions of the extracellular portions of the Type II TGF- beta receptor, so long as they bind TGF- beta with high affinity. Although the sequence of a given "fragment" is based most preferably on the native TGF- beta receptor II extracellular region, the definition also comprises analogs of

proteins of the invention which have high affinity for TGF- beta . Such analogs include those made by conservative substitutions of amino acids, as well as those made by mutated cells synthesizing the fragment.

Family members of TGF-beta receptors useful in the methods of the invention include any of the naturally-occurring native proteins including allelic, phylogenetic counterparts or other variants thereof, whether naturally-sourced or chemically produced including muteins or mutant proteins, as well as recombinant forms and new, active members of the family. The polypeptides include an amino acid sequence at least 60%, 80%, 90%, 95%, 98%, or 99% homologous to an amino acid sequence from SEQ ID NOS: 8 or 9. The polypeptide can also include an amino acid sequence essentially the same as an amino acid sequence in SEQ ID NOS: 8 or 9. The polypeptide is at least 5, 10, 20, 50, 100, or 150 amino acids in length and includes at least 5, preferably at least 10, more preferably at least 20, most preferably at least 50, 100, or 150 contiguous amino acids from SEQ ID NOS: 8 or 9.

Polypeptides of the invention include those which arise as a result of the existence of multiple genes, alternative transcription events, alternative RNA splicing events, and alternative translational and posttranslational events. The polypeptide can be made entirely by synthetic means or can be expressed in systems, e.g., cultured cells, which result in substantially the same posttranslational modifications present when the protein is expressed in a native cell, or in systems which result in the omission of posttranslational modifications present when expressed in a native cell.

#### B. Isolated Polynucleotide Sequences

Preferred polynucleotides of the invention are derived from polynucleotides that encode, upon expression, the wild-type TGF-beta receptor (e.g. SEQ ID NOS.: 1-4, 10 and 12 ) See also U.S. Patent 5,693,607. A cDNA encoding a TGF-beta receptor Type II molecule (i.e. nucleotides numbered as 832-1311 of SEQ ID NO.: 2 or SEQ. ID. NO:4) is a complementary DNA (cDNA) sequence encoding for TGF-beta receptor. Other members of the TGF-beta receptor family are presented as wild-type TGF-beta Type I polynucleotide (REF), and wild-type Type III polynucleotide (REF).

Moreover, the isolated, polynucleotides depicted in SEQ ID NOS. 1-4, 10 and 12 can be altered to provide for functionally equivalent polynucleotides. A polynucleotide is "functionally equivalent" compared with those of SEQ ID NOS.: 1-4, 10 and 12 if it satisfies at least one of the following conditions: (a): the "functional equivalent" is a polynucleotide that hybridizes to any of

-29-

the foregoing sequences (SEQ ID NOS. 1-4, 10, 12) under standard hybridization conditions. Most preferably, it encodes a TGF-beta receptor protein having the same biological activity as wild-type TGF-beta receptor; and (b) the "functional equivalent" is a polynucleotide that codes on expression for an amino acid sequence encoded by any of the polynucleotides of SEQ ID NOS. 1-5 4, 10 and 12.

Due to the degeneracy of the nucleotide coding sequences, other polynucleotides may be used to encode TGF-beta receptors or fusions thereof. For TGF-beta Type II receptor, these include all, or portions of DNA encoding SEQ ID NOS.: 8 or 9, which are altered by the substitution of different codons that encode the same amino acid residue within the sequence, thus 10 producing a silent change. Such altered sequences are regarded as equivalents of SEQ ID NOS.: 8 or 9. For example, Phe(f) is coded for by two codons, TTC or TTT, Try (Y) is coded for by TAC or TAT and His (H) is coded for by CAC or CAT. On the other hand, Trp (W) is coded for by a single codon, TGG. Accordingly, it will be appreciated that for a given DNA sequence encoding a 15 particular protein there will be many DNA degenerate sequences that will code for it. These degenerate DNA sequences are considered within the scope of this invention.

Fusion proteins of the invention incorporating the rabbit TGF-beta Type II receptor are shown in SEQ ID NOS: 2 and 8, for the cDNA and deduced amino acids sequences, respectively. Fusion proteins incorporating the human TGF-beta Type II receptor are shown in SEQ ID NOS: 4 and 9 for the cDNA and deduced amino acid sequences, respectively.

20 The preferred TGF-beta RII:Fc proteins of the invention include the novel "junction" DNA sequence SEQ ID NO: 10 and amino acid SEQ ID NO: 11. SEQ ID NO: 10 represents the 11 triplet codons on either side of the CTG/GTC junction between the rabbit TGF-beta RII DNA and the DNA of the immunoglobulin. In SEQ ID NO: 10, the TGF-beta sequence ends after the CTG triplet and the immunoglobulin sequence begins at the GTC triplet. The 25 corresponding deduced rabbit amino acid "junction" sequence is represented in SEQ ID NO: 11 in which the end of the TGF-beta receptor sequence is the leucine and the beginning of the immunoglobulin sequence is the valine immediately thereafter. Corresponding "junction" human cDNA and amino acid sequences are SEQ ID NOS.: 12 and 13, respectively. In SEQ ID NO: 2, the corresponding junction begins at the triplet starting from nucleotide 1309 and ends 30 at the triplet starting with nucleotide 1312.

It might be that SEQ ID NOS: 10 and 12 are the minimum DNA needed for hybridization under standard conditions to any DNA sequence encoding any TGF-beta receptor:Fc fusion protein. Nevertheless, provided that the whole probe hybridizes to both sides of the junction

-30-

and both sides of the TGF-beta receptor/constant region junction participate in the hybridization, smaller sequences may exist. Furthermore, persons having ordinary skill in the art will understand that DNA sequences larger than SEQ ID NOS: 10 and 12 will be suitable for hybridization as well. One of ordinary skill in the art can test if a particular probe such as 5 SEQ ID NOS: 10 and 12 are capable of hybridizing on both sides of the junction by labelling the 5' end of either a single strand sense oligonucleotide or a single strand anti-sense oligonucleotide with an appropriately labelled phosphate of ATP using polynucleotide kinase. A sequence of the invention must hybridize to, and thus be labelled by both oligonucleotide probes. It is further understood that the invention encompasses fully degenerate sequences 10 encoding the junction SEQ ID NOS: 10 and 12.

Like most mammalian genes, mammalian TGF-beta receptors are presumably encoded by multi-exon genes. Alternative mRNA constructs which can be attributed to different mRNA splicing events following transcription, and which share large regions of identity or similarity with the cDNAs claimed herein may also be used. The vector containing the TGF-beta RII:Fc cDNA clone, was used to express and purify soluble TGF-beta RII:Fc. Plasmid 15 which expresses the fusion protein has been deposited with the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Md. 20852, U.S.A. (Accession No.

) under the name \_\_\_\_\_.

Other mammalian TGF-beta receptor cDNAs may be isolated by using an appropriate 20 human TGF-beta receptor DNA sequence as a probe for screening a particular mammalian cDNA library by cross-species hybridization. Mammalian TGF-beta receptor used in the present invention includes, by way of example, primate, human, murine, canine, feline, bovine, equine and porcine TGF-beta receptor. Mammalian TGF-beta receptors can be obtained by cross species 25 hybridization, using a single stranded cDNA derived from the human TGF-beta receptor DNA sequence as a hybridization probe to isolate TGF-beta receptor cDNAs from mammalian cDNA libraries.

### III. Production of Recombinant Polypeptides

30 The isolated polypeptides described herein can be produced by any suitable method known in the art. Such methods range from direct protein synthetic methods to constructing a DNA sequence encoding isolated polypeptide sequences and expressing those sequences in a suitable

transformed host. For example, cDNA may be obtained by screening a human cDNA library with a labeled DNA fragment encoding the polypeptides of SEQ ID NOS: 8, 9, 11 or 13 and identifying positive clones by autoradiography. Further rounds of plaque purification and hybridization are performed using conventional methods.

5 In one embodiment of a recombinant method, a DNA sequence is constructed by isolating or synthesizing a DNA sequence encoding a wild-type protein of interest. Optionally, the sequence may be mutagenized by site-specific mutagenesis to provide functional analogs thereof. See, e.g. Zoeller et al., Proc.-Nat Acad. Sci. USA 81:5662-5666 (1984) and United States Patent 4,588,585. Another method of constructing a DNA sequence encoding a  
10 polypeptide of interest would be by chemical synthesis using an oligonucleotide synthesizer. Such oligonucleotides may be preferably designed based on the amino acid sequence of the desired polypeptide, and preferably selecting those codons that are favored in the host cell in which the recombinant polypeptide of interest will be produced.

15 Standard methods may be applied to synthesize an isolated polynucleotide sequence encoding a isolated polypeptide of interest. For example, a complete amino acid sequence may be used to construct a back-translated gene. See Maniatis et al., *supra*. Further, a DNA oligomer containing a nucleotide sequence coding for the particular isolated polypeptide may be synthesized. For example, several small oligonucleotides coding for portions of the desired polypeptide may be synthesized and then ligated. The individual oligonucleotides typically  
20 contain 5' or 3' overhangs for complementary assembly.

Once assembled (by synthesis, site-directed mutagenesis or another method), the mutant DNA sequences encoding a particular isolated polypeptide of interest will be inserted into an expression vector and operatively linked to an expression control sequence appropriate for expression of the protein in a desired host. Proper assembly may be confirmed by nucleotide  
25 sequencing, restriction mapping, and expression of a biologically active polypeptide in a suitable host. As is well known in the art, in order to obtain high expression levels of a transfected gene in a host, the gene must be operatively linked to transcriptional and translational expression control sequences that are functional in the chosen expression host.

30 A. Expression of Recombinant TGF-beta Receptor

Recombinant expression vectors are preferably used to amplify or express DNA encoding TGF-beta receptor fusions. Recombinant expression vectors are replicable DNA constructs which have synthetic or cDNA-derived DNA fragments encoding TGF-beta receptor

5 fusions or bioequivalent analogs operatively linked to suitable transcriptional or translational regulatory elements derived from mammalian, microbial, viral or insect genes. A transcriptional unit generally comprises an assembly of (1) a genetic element or elements having a regulatory role in gene expression, for example, transcriptional promoters or enhancers, (2) a structural or coding sequence which is transcribed into mRNA and translated into protein, and (3) appropriate transcription and translation initiation and termination sequences, as described in detail below. Such regulatory elements may include an operator sequence to control transcription. The ability to replicate in a host, usually conferred by an origin of replication, and a selection gene to facilitate recognition of transformants may additionally be incorporated.

10 10 DNA regions are operatively linked when they are functionally related to each other. For example, DNA for a signal peptide (secretory leader) is operatively linked to DNA for a polypeptide if it is expressed as a precursor which participates in the secretion of the polypeptide; a promoter is operatively linked to a coding sequence if it controls the transcription of the sequence; or a ribosome binding site is operatively linked to a coding

15 15 sequence if it is positioned so as to permit translation. Generally, operatively linked means contiguous and, in the case of secretory leaders, contiguous and in reading frame. Structural elements intended for use in yeast expression systems preferably include a leader sequence enabling extracellular secretion of translated protein by a host cell. Alternatively, where recombinant protein is expressed without a leader or transport sequence, it may include an N-terminal methionine residue. This residue may optionally be subsequently cleaved from the

20 20 expressed recombinant protein to provide a final product.

25 DNA sequences encoding mammalian TGF-beta receptors which are to be expressed as a fusion in microorganism may preferably contain introns that could prematurely terminate transcription of DNA into mRNA since such premature termination of transcription may be desirable, for example, where it would result in mutants having advantageous C-terminal truncations, for example, deletion of a transmembrane region to yield a soluble receptor not bound to the cell membrane. Due to code degeneracy, there can be considerable variation in nucleotide sequences encoding the same amino acid sequence. As discussed above, other embodiments include sequences capable of hybridizing to the sequences of the provided cDNA under standard conditions (50 degrees C., 2 x SSC) and other sequences hybridizing or degenerate to those which encode biologically active proteins of the invention.

30

The choice of expression control sequence and expression vector will depend upon the choice of host. A wide variety of expression host/vector combinations may be employed.

-33-

Useful expression vectors for eukaryotic hosts, include, for example, vectors comprising expression control sequences from SV40, bovine papilloma virus, adenovirus and cytomegalovirus. Useful expression vectors for bacterial hosts include known bacterial plasmids, such as plasmids from *Escherichia coli*, including pCR1, pBR322, pMB9 and their derivatives, wider host range plasmids, such as M13 and filamentous single-stranded DNA phages. Preferred *E. coli* vectors include pL vectors containing the lambda phage pL promoter (U.S. Patent 4,874,702), pET vectors containing the T7 polymerase promoter (Studier et al., *Methods in Enzymology* 185: 60-89, 1990 1) and the pSP72 vector (Kaelin et al., *supra*). Useful expression vectors for yeast cells, for example, include the 2  $\mu$  and centromere plasmids.

In addition, any of a wide variety of expression control sequences may be used in these vectors. Such useful expression control sequences include the expression control sequences associated with structural genes of the foregoing expression vectors. Examples of useful expression control sequences include, for example, the early and late promoters of SV40 or adenovirus, the *lac* system, the *trp* system, the *TAC* or *TRC* system, the major operator and promoter regions of phage lambda, for example pL, the control regions of fd coat protein, the promoter for 3-phosphoglycerate kinase or other glycolytic enzymes, the promoters of acid phosphatase, e.g., Pho5, the promoters of the yeast *alpha*-mating system and other sequences known to control the expression of genes of prokaryotic or eukaryotic cells and their viruses, and various combinations thereof.

Recombinant TGF-beta receptor DNA or recombinant TGF-beta R:Fc DNA is expressed or amplified in a recombinant expression system comprising a substantially homogeneous monoculture of a suitable host which have stably integrated (by transformation or transfection) a recombinant transcriptional unit into chromosomal DNA or carry the recombinant transcriptional unit as a component of a resident plasmid. Generally, cells constituting the system are the progeny of a single ancestral transformant. Recombinant expression systems as defined herein will express heterologous protein upon induction of the regulatory elements linked to the DNA sequence or synthetic gene to be expressed.

Suitable host cells for expression of mammalian TGF-beta receptor and its fusion proteins include prokaryotes, yeast or higher eukaryotic cells under the control of appropriate promoters. Prokaryotes include gram negative or gram positive organisms, for example *E. coli* or bacilli. Higher eukaryotic cells include established cell lines of mammalian origin as described below. Cell-free translation systems could also be employed to produce mammalian

TGF-beta receptor and TGF-beta R:Fc using RNAs derived from the DNA constructs of the present invention. Appropriate cloning and expression vectors for use with bacterial, fungal, yeast, and mammalian cellular hosts are described by Pouwels et al. (Cloning Vectors: A Laboratory Manual, Elsevier, N.Y., 1985), the relevant disclosure of which is hereby incorporated by reference.

5 Recombinant proteins of the invention may also be expressed in yeast hosts, preferably from the *Saccharomyces* species, such as *S. cerevisiae*. Yeast of other genera, such as *Pichia* or *Kluyveromyces* may also be employed. Yeast vectors will generally contain an origin of replication from the 2 mu yeast plasmid or an autonomously replicating sequence (ARS),  
10 promoter, DNA encoding proteins of the invention and DNA sequences for polyadenylation and transcription termination and a selection gene. Preferably, yeast vectors will include an origin of replication and selectable marker permitting transformation of both yeast and *E. coli.*, e.g., the ampicillin resistance gene of *E. coli.* and *S. cerevisiae* TRP1 or URA3 gene, which provides a selection marker for a mutant strain of yeast lacking the ability to grow in  
15 tryptophan, and a promoter derived from a highly expressed yeast gene to induce transcription of a structural sequence downstream. The presence of the TRP1 or URA3 lesion in the yeast host cell genome then provides an effective environment for detecting transformation by growth in the absence of tryptophan or uracil.

20 Suitable promoter sequences in yeast vectors include the promoters for metallothionein, 3-phosphoglycerate kinase (Hitzeman et al., J. Biol. Chem. 255:2073, 1980) or other glycolytic enzymes (Hess et al., J. Adv. Enzyme Reg. 7:149, 1968; and Holland et al., Biochem. 7:4900, 1978), such as enolase, glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose isomerase, and glucokinase. Suitable vectors and promoters for use in yeast expression are further described in R. Hitzeman et al., EPA 73,657. Preferred yeast vectors can be assembled using DNA sequences from pUC18 for selection and replication in *E. coli.* (Amp' gene and origin of replication) and yeast DNA sequences including a glucose-repressible ADH2 promoter and *alpha*-factor secretion leader. The ADH2 promoter has been described by Russell et al. (J. Biol. Chem. 258:2674, 1982) and Beier et al. (Nature 300:724, 1982). The yeast *alpha*-factor leader, which directs secretion of heterologous proteins, can be inserted between the promoter and the structural gene to be expressed. See, e.g., Kurjan et al., Cell 30:933, 1982; and Bitter et al., Proc. Natl. Acad. Sci. U.S.A. 81:5330, 1984. The leader sequence may be  
25  
30

modified to contain, near its 3' end, one or more useful restriction sites to facilitate fusion of the leader sequence to foreign genes.

Suitable yeast transformation protocols are known to those of skill in the art; an exemplary technique is described by Hinnen et al., Proc. Natl. Acad. Sci. U.S.A. 75:1929, 1978 5 as described by Sherman et al., Laboratory Course Manual for Methods in Yeast Genetics, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., 1986.

Various mammalian or insect cell culture systems are also advantageously employed to express recombinant protein. Expression of recombinant proteins in mammalian cells is particularly preferred because such proteins are generally correctly folded, appropriately 10 modified and completely functional. Examples of suitable mammalian host cell lines include the COS-7 lines of monkey kidney cells, described by Gluzman (Cell 23:175, 1981), and other cell lines capable of expressing an appropriate vector including, for example, L cells, C127, 15 3T3, Chinese hamster ovary (CHO), HeLa and BHK cell lines. Mammalian expression vectors may comprise nontranscribed elements such as an origin of replication, a suitable promoter and enhancer linked to the gene to be expressed, and other 5' or 3' flanking nontranscribed sequences, and 5' or 3' nontranslated sequences, such as necessary ribosome binding sites, a polyadenylation site, splice donor and acceptor sites, and transcriptional termination sequences. 20 Baculovirus systems for production of heterologous proteins in insect cells are reviewed by Luckow and Summers, Bio/Technology 6:47 (1988).

Recombinant expression vectors comprising cDNAs are stably integrated into a host 25 cell's DNA. Elevated levels of expression product is achieved by selecting for cell lines having amplified numbers of vector DNA. Cell lines having amplified numbers of vector DNA are selected, for example, by transforming a host cell with a vector comprising a DNA sequence which encodes an enzyme which is inhibited by a known drug. The vector may also comprise a DNA sequence which encodes a desired protein. Alternatively, the host cell may be co-transformed with a second vector which comprises the DNA sequence which encodes the 30 desired protein. The transformed or co-transformed host cells are then cultured in increasing concentrations of the known drug, thereby selecting for drug-resistant cells. Such drug-resistant cells survive in increased concentrations of the toxic drug by over-production of the enzyme which is inhibited by the drug, frequently as a result of amplification of the gene encoding the enzyme. Where drug resistance is caused by an increase in the copy number of the vector DNA encoding the inhibitable enzyme, there is a concomitant co-amplification of the vector DNA encoding the desired protein in the host cell's DNA.

-36-

A preferred system for such co-amplification uses the gene for dihydrofolate reductase (DHFR), which can be inhibited by the drug methotrexate (MTX). To achieve co-amplification, a host cell which lacks an active gene encoding DHFR is either transformed with a vector which comprises DNA sequence encoding DHFR and a desired protein, or is co-transformed 5 with a vector comprising a DNA sequence encoding DHFR and a vector comprising a DNA sequence encoding the desired protein. The transformed or co-transformed host cells are cultured in media containing increasing levels of MTX, and those cells lines which survive are selected.

A particularly preferred co-amplification system uses the gene for glutamine synthetase (GS), which is responsible for the synthesis of glutamate and ammonia using the hydrolysis of ATP to ADP and phosphate to drive the reaction. GS is subject to inhibition by a variety of inhibitors, for example methionine sulphoximine (MSX). Thus, proteins of the invention can be expressed in high concentrations by co-amplifying cells transformed with a vector comprising the DNA sequence for GS and a desired protein, or co-transformed with a vector comprising a 10 DNA sequence encoding GS and a vector comprising a DNA sequence encoding the desired protein, culturing the host cells in media containing increasing levels of MSX and selecting for surviving cells. The GS co-amplification system, appropriate recombinant expression vectors and cells lines, are described in the following PCT applications: WO 87/04462, WO 89/01036, 15 WO 89/10404 and WO 86/05807.

20 Recombinant proteins are preferably expressed by co-amplification of DHFR or GS in a mammalian host cell, such as Chinese Hamster Ovary (CHO) cells, or alternatively in a murine myeloma cell line, such as SP2/0-Ag14 or NS0 or a rat myeloma cell line, such as YB2/3.0-Ag20, disclosed in PCT applications WO/89/10404 and WO 86/05807.

25 It should be understood that not all vectors and expression control sequences will function equally well to express a given isolated polypeptide. Neither will all hosts function equally well with the same expression system. However, one of skill in the art may make a selection among these vectors, expression control systems and hosts without undue experimentation.

#### B. Purification of Recombinant TGF-betaRII:Fc

30 The proteins produced by a transformed host can be purified according to any suitable method. Such standard methods include chromatography (e.g., ion exchange, affinity and sizing column chromatography), centrifugation, differential solubility, or by any other standard technique for protein purification. Affinity tags such as hexahistidine, maltose

binding domain, influenza coat sequence and glutathione-S-transferase can be attached to the protein to allow easy purification by passage over an appropriate affinity column. Isolated proteins can also be physically characterized using such techniques as proteolysis, nuclear magnetic resonance and x-ray crystallography.

5 For example, supernatants from systems which secrete recombinant protein into culture media can be first concentrated using a commercially available protein concentration filter, for example, an Amicon or Millipore Pellicon ultrafiltration unit. Following the concentration step, the concentrate can be applied to a suitable purification matrix. For example, a suitable affinity matrix can comprise a TGF-beta or lectin or antibody molecule or Protein A bound to a  
10 suitable support. Alternatively, an anion exchange resin can be employed, for example, a matrix or substrate having pendant diethylaminoethyl (DEAE) groups. The matrices can be acrylamide, agarose, dextran, cellulose or other types commonly employed in protein purification. Alternatively, a cation exchange step can be employed. Suitable cation exchangers include various insoluble matrices comprising sulfopropyl or carboxymethyl groups.

15 Sulfopropyl groups are preferred. Finally, one or more reversed-phase high performance liquid chromatography (RP-HPLC) steps employing hydrophobic RP-HPLC media, e.g., silica gel having pendant methyl or other aliphatic groups, can be employed to further purify a TGF-betaRII:Fc composition. Some or all of the foregoing purification steps, in various combinations, can also be employed to provide a homogeneous recombinant protein.

20 Recombinant protein produced in bacterial culture is usually isolated by initial extraction from cell pellets, followed by one or more concentration, salting-out, aqueous ion exchange or size exclusion chromatography steps. Finally, high performance liquid chromatography (HPLC) can be employed for final purification steps. Microbial cells employed in expression of recombinant mammalian TGF-beta receptor can be disrupted by any convenient method, including freeze-thaw cycling, sonication, mechanical disruption, or use of cell lysing agents.

25 Fermentation of yeast which express mammalian TGF-beta receptor fusion as a secreted protein greatly simplifies purification. Secreted recombinant protein resulting from a large-scale fermentation can be purified by methods analogous to those disclosed by Urdal et al. (J. Chromatog. 296:171, 1984). This reference describes two sequential, reversed-phase HPLC steps for purification of recombinant human GM-CSF on a preparative HPLC column.

### C. Production of Fragments and Analogs

-38-

Fragments of an isolated protein (e.g., fragments of SEQ ID NO: 8) can also be produced efficiently by recombinant methods, by proteolytic digestion, or by chemical synthesis, using methods known to those of skill in the art. In recombinant methods, internal or terminal fragments of a polypeptide can be generated by removing one or more nucleotides 5 from one end (for a terminal fragment) or both ends (for an internal fragment) of a DNA sequence which encodes for the isolated polypeptide. Expression of the mutagenized DNA produces polypeptide fragments. Digestion with "end nibbling" endonucleases can also generate DNAs which encode an array of fragments. DNAs which encode fragments of a protein can also be generated by random shearing, restriction digestion or a combination or 10 both.

TGF-beta receptor fragments can be generated directly from intact TGF-beta receptor proteins. Peptides can be specifically cleaved by proteolytic enzymes, including, but not limited to plasmin, thrombin, trypsin, chymotrypsin or pepsin. Each of these enzymes is specific for the type of peptide bond it attacks. Trypsin catalyzes the hydrolysis of peptide bonds in which the 15 carbonyl group is from a basic amino acid, usually arginine or lysine. Pepsin and chymotrypsin catalyse the hydrolysis of peptide bonds from aromatic amino acids, such as tryptophan, tyrosine and phenylalanine. Alternate sets of cleaved protein fragments are generated by preventing cleavage at a site which is susceptible to a proteolytic enzyme. For instance, reaction of the  $\epsilon$ -amino acid groups of lysine with ethyltrifluorothioacetate in mildly basic solution 20 yields blocked amino acid residues whose adjacent peptide bond is no longer susceptible to hydrolysis by trypsin. Proteins can be modified to create peptide linkages that are susceptible to proteolytic enzymes. For instance, alkylation of cysteine residues with  $\beta$ -halo ethylamines yields peptide linkages that are hydrolyzed by trypsin (Lindley, *Nature* 178: 647 (1956)). In addition, chemical reagents that cleave peptide chains at specific residues can be used. For 25 example, cyanogen bromide cleaves peptides at methionine residues (Gross and Witkip, *J. Am. Chem. Soc.*, 83: 1510 (1961)). Thus, by treating proteins with various combinations of modifiers, proteolytic enzymes and/or chemical reagents, the proteins may be divided into fragments of a desired length with no overlap of the fragments, or divided into overlapping fragments of a desired length.

30 Fragments can also be chemically synthesized using techniques known in the art such as the Merrifield solid phase F moc or t-Boc chemistry. **Merrifield, Recent Progress in Hormone Research 23: 451 (1967)**

**D. Production of Altered DNA and Peptide Sequences: Random Methods**

Amino acid sequence variants of a protein (such as variants of SEQ ID NO.: 8) can be prepared by random mutagenesis of DNA which encodes the protein or a particular portion thereof. Useful methods include PCR mutagenesis and saturation mutagenesis. A library of random amino acid sequence variants can also be generated by the synthesis of a set of degenerate oligonucleotide sequences. Methods of generating amino acid sequence variants of a given protein using altered DNA and peptides are well-known in the art. The following examples of such methods are not intended to limit the scope of the present invention, but merely serve to illustrate representative techniques. Persons having ordinary skill in the art will recognize that other methods are also useful in this regard.

**PCR Mutagenesis:** Briefly, *Taq* polymerase (or another polymerase) is used to introduce random mutations into a cloned fragment of DNA (See Leung et al., *Technique* 1: 11-15 (1989)). PCR conditions are chosen so that the fidelity of DNA synthesis is reduced by *Taq* DNA polymers using, for instance, a dGTP/dATP ratio of five and adding  $Mn^{+2}$  to the PCR reaction. The pool of amplified DNA fragments is inserted into appropriate cloning vectors to provide random mutant libraries.

**Saturation Mutagenesis:** One method is described generally in Mayers et al., *Science*, 229: 242 (1989). Briefly, the technique includes generation of mutations by chemical treatment or irradiation of single stranded DNA *in vitro*, and synthesis of a cDNA strand. The mutation frequency is modulated by the severity of the treatment and essentially all possible base substitutions can be obtained.

**Degenerate Oligonucleotide Mutagenesis:** A library of homologous peptides can be generated from a set of degenerate oligonucleotide sequences. Chemical synthesis of degenerate sequences can be performed in an automatic DNA synthesizer, and the synthetic genes then ligated into an appropriate expression vector. See Itakura et al., *Recombinant DNA*, Proc. 3rd Cleveland Symposium on Macromolecules, pp. 273-289 (A.G. Walton, ed.), Elsevier, Amsterdam, 1981.

#### E. Production of Altered DNA and Peptide Sequences: Directed Methods

Non-random, or directed, mutagenesis provides specific sequences or mutations in specific portions of a polynucleotide sequence that encodes an isolated polypeptide, to provide variants which include deletions, insertions or substitutions of residues of the known amino acid sequence of the isolated polypeptide. The mutation sites may be modified individually or in series, for instance by: (1) substituting first with conserved amino acids and then with more radical choices depending on the results achieved; (2) deleting the target residue; or (3) inserting residues of the same or a different class adjacent to the located site, or combinations of options 1-3.

10

Alanine scanning Mutagenesis: This method locates those residues or regions of a desired protein that are preferred locations for mutagenesis. See Cunningham and Wells, *Science* 244: 1081-1085 (1989). In alanine screening, a residue or group of target residues are selected and replaced by alanine or polyalanine. This replacement can affect the interaction of the amino acid with neighboring amino acids and/or with the surrounding aqueous or membrane environment. Those having functional sensitivity to the substitutions are then refined by introducing further or other variants at, or for, the sites of substitution.

20

Oligonucleotide-Mediated Mutagenesis: One version of this method may be used to prepare substitution, deletion, and insertion variants of DNA. See Adelman et al., *DNA* 2:183 (1983). Briefly, the desired DNA is altered by hybridizing an oligonucleotide primer encoding a DNA mutation to a DNA template which typically is the single stranded form of a plasmid or phage containing the unaltered or wild-type DNA sequence template of the desired protein (e.g., the protein). After hybridization, a DNA polymerase is used to make the second and complementary strand of DNA of the template that will incorporate the oligonucleotide primer, and will code for the selected alteration in the desired DNA sequence. Generally, oligonucleotides of at least 25 nucleotides in length are used. An optimal oligonucleotide will have 12 to 15 nucleotides that are completely complementary to the template on either side of the mutation. This ensures that the oligonucleotide will hybridize properly to the single-stranded DNA template molecule.

30

Cassette Mutagenesis: This method (Wells et al., *Gene* 34: 315 (1985)) requires a plasmid or other vector that contains the protein subunit DNA to be mutated. The codon(s) in the protein

subunit DNA are identified and there is inserted a unique restriction endonuclease site on each side of the identified mutation site(s), using the above-described oligonucleotide-directed mutagenesis method. The plasmid is then cut at these sites to linearize it. A double-stranded oligonucleotide encoding the sequence of the DNA between the restriction sites but containing the desired mutation(s) is synthesized using standard procedures. The two strands are synthesized separately and then hybridized together using standard methods. This double-stranded oligonucleotide is the "cassette" and it has 3' and 5' ends that are compatible with the ends of the linearized plasmid so that it can be directly ligated therein. The plasmid now contains the mutated desired protein subunit DNA sequence.

10

Combinatorial Mutagenesis: In one version of this method (Ladner et al., WO 88/06630), the amino acid sequences for a group of homologs or other related proteins are aligned, preferably to promote the highest homology possible. All of the amino acids which appear at a given position of the aligned sequences can be selected to create a degenerate set of combinatorial sequences. The variegated library is generated by combinatorial mutagenesis at the nucleic acid level, and is encoded by a variegated gene library. For instance, a mixture of synthetic oligonucleotides can be enzymatically ligated into the gene sequence such that the degenerate set of potential sequences are expressible as individual peptides, or alternatively, as a set of proteins containing the entire set of degenerate sequences.

15

#### IV. Other Variants of Isolated Polypeptides

Derivatives of proteins of the invention also include various structural forms of the primary protein which retain biological activity. Due to the presence of ionizable amino and 25 carboxyl groups, for example, a TGF-beta receptor fusion protein may be in the form of acidic or basic salts, or may be in neutral form. Individual amino acid residues may also be modified by oxidation or reduction. The primary amino acid structure (e.g., of the TGF-beta RII moiety) may be modified by forming covalent or aggregative conjugates with other chemical moieties, such as glycosyl groups, lipids, phosphate, acetyl groups and the like, or by creating amino acid 30 sequence mutants.

Covalent derivatives of the TGF-beta receptor may be prepared by linking particular functional groups to TGF-beta receptor amino acid side chains or at the N- or C-termini. Other derivatives of TGF-beta RII:Fc include covalent or aggregative conjugates of TGF-beta RII or

its fragments with other proteins or polypeptides, such as by synthesis in recombinant culture as additional N-terminal or C-terminal fusions. For example, the conjugated peptide may be a signal (or leader) polypeptide sequence at the N-terminal region of the protein which co-translationally or post-translationally directs transfer of the protein from its site of synthesis to 5 its site of function inside or outside of the cell membrane or wall (e.g., the yeast alpha -factor leader). TGF-beta receptor proteins can comprise peptides added to facilitate purification or identification of TGF-beta receptor (e.g., poly-His). The amino acid sequence of TGF-beta receptor can also be linked to the peptide Asp-Tyr-Lys-Asp-Asp-Asp-Lys (DYKDDDDK) (Hopp et al., Bio/Technology 6:1204,1988.) The latter sequence is highly antigenic and 10 provides an epitope reversibly bound by a specific monoclonal antibody, enabling rapid assay and facile purification of expressed recombinant protein. This sequence is also specifically cleaved by bovine mucosal enterokinase at the residue immediately following the Asp-Lys pairing. Fusion proteins capped with this peptide may also be resistant to intracellular degradation in *E. coli*.

15 Polyvalent forms of TGF-beta receptor are useful since they possess multiple TGF-beta receptor binding sites for TGF-beta ligand. For example, a bivalent soluble TGF-beta receptor may consist of two tandem repeats of amino acids numbered 1-160 of SEQ. ID.NO.: 8 or 9 separated by a linker region, the repeats bound to the immunoglobulin constant domain. Alternate polyvalent forms may also be constructed, for example, by chemically coupling TGF- 20 beta receptor Fc fusions to any clinically acceptable carrier molecule, a polymer selected from the group consisting of Ficoll, polyethylene glycol or dextran using conventional coupling techniques. Alternatively, TGF-beta receptor fusion may be chemically coupled to biotin, and the biotin-TGF-beta receptor Fc conjugate then allowed to bind to avidin, resulting in tetravalent avidin/biotin/TGF-beta receptor molecules. TGF-beta receptor Fc fusions may also 25 be covalently coupled to dinitrophenol (DNP) or trinitrophenol (TNP) and the resulting conjugate precipitated with anti-DNP or anti-TNP-IgM, to form decameric conjugates with a valency of 10 for TGF-beta receptor binding sites.

Functional mutant analogs of the TGF-betaRII:Fc fusion having inactivated N-glycosylation sites can be produced by oligonucleotide synthesis and ligation or by site-specific 30 mutagenesis techniques. These analog proteins can be produced in a homogeneous, reduced-carbohydrate form in good yield using yeast expression systems. N-glycosylation sites in eukaryotic proteins are characterized by the amino acid triplet Asn-A1-Z, where A1 is any amino acid except Pro, and Z is Ser or Thr. In this sequence, Asn provides a side chain amino

group for covalent attachment of carbohydrate. Such a site can be eliminated by substituting another amino acid for Asn or for residue Z, deleting Asn or Z, or inserting a non-Z amino acid between A1 and Z, or an amino acid other than Asn between Asn and A1. TGF-beta receptor derivatives may also be obtained by mutations of TGF-beta receptor or its subunits.

5 Bioequivalent analogs of TGF-beta receptor proteins may be constructed by, for example, making various substitutions of residues or sequences or deleting terminal or internal residues or sequences not needed for biological activity.

Other analogs include TGF-beta RII:Fc protein or its biologically active fragments whose sequences differ from SEQ ID NOS: 2 or 4 by one or more conservative amino acid 10 substitutions or by one or more non conservative amino acid substitutions, or by deletions or insertions which do not abolish the isolated protein's biological activity. Conservative substitutions typically include the substitution of one amino acid for another with similar characteristics such as substitutions within the following groups: valine, alanine and glycine; leucine and isoleucine; aspartic acid and glutamic acid; asparagine and glutamine; serine and 15 threonine; lysine and arginine; and phenylalanine and tyrosine. The non-polar hydrophobic amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan and methionine. The polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine and glutamine. The positively charged (basic) amino acids include arginine, lysine and histidine. The negatively charged (acidic) amino acids include aspartic acid and glutamic 20 acid. Other conservative substitutions can be readily known by workers of ordinary skill. For example, for the amino acid alanine, a conservative substitution can be taken from any one of D-alanine, glycine, beta-alanine, L-cysteine and D-cysteine. For lysine, a replacement can be any one of D-lysine, arginine, D-arginine, homo-arginine, methionine, D-methionine, ornithine, or D-ornithine.

25 Generally, substitutions that may be expected to induce changes in the functional properties of isolated polypeptides are those in which: (i) a polar residue, e.g., serine or threonine, is substituted for (or by) a hydrophobic residue, e.g., leucine, isoleucine, phenylalanine, or alanine; (ii) a cysteine residue is substituted for (or by) any other residue; (iii) a residue having an electropositive side chain, e.g., lysine, arginine or histidine, is substituted 30 for (or by) a residue having an electronegative side chain, e.g., glutamic acid or aspartic acid; or (iv) a residue having a bulky side chain, e.g., phenylalanine, is substituted for (or by) one not having such a side chain, e.g., glycine.

Included in the invention are isolated molecules that are: allelic variants, natural mutants, induced mutants, proteins encoded by DNA that hybridize under high or low stringency conditions to a nucleic acid which encodes a polypeptide such as SEQ. ID. NOS. 8 or 9 and polypeptides specifically bound by antisera to peptides, especially by antisera to an active site or binding site of . All variants described herein are expected to: (i) retain the biological function of the original protein

#### V. Utilities

This invention provides for administering to an individual with a medical condition a sufficient amount of TGF-beta receptor fusion protein, such as TGF-beta RII:Fc, to reduce TGF- beta activity in the individual. This invention further provides for delivering TGF-beta RII:Fc to a site where TGF- beta is in excess, such as in disease states characterized by fibroproliferation and immunosuppression such as is associated with infectious disease.

While not wishing to be bound by any particular theory, it appears that the TGF- beta RII:Fc regulates TGF- beta activity by competing for TGF- beta with cell-surface receptors. It is further believed that it inactivates TGF- beta by removing it from the free pool of TGF- beta available to interact with cell surface receptors. Depending on the pharmacologic properties of clearance, the TGF beta -RII:Fc/TGF- beta complex is removed from the site of TGF- beta. This complexing with excess TGF- beta reduces the amount of free TGF- beta With less TGF- beta available to complex with cell receptors, TGF- beta induced fibroproliferation slows down, resulting in stasis of the disease state.

The administration of proteins of the invention fragments of the present invention may be used in fibroproliferative disorders. As mentioned above, animal models of glomerulonephritis have shown good results with anti-TGF- beta antibodies blocking excess TGF- beta . These antibodies will be difficult to deliver because they have a high molecular weight and they may result in severe allergic reactions when they are derived from other species. Thus, it would be preferable to administer a lower molecular weight, native protein or close analog, such as TGF- beta RII:Fc, in glomerulonephritis. Kidney disorders associated with TGF- beta excess include, but are not limited to, mesangial proliferative glomerulonephritis, crescentic glomerulonephritis, diabetic nephropathy, renal interstitial fibrosis, renal fibrosis in transplant patients receiving cyclosporin, and HIV- associated nephropathy. These conditions are associated with overproduction of fibrous tissue formation which administration of TGF-beta RII:Fc should suppress.

As TGF-beta RII by itself is not known to have an effect aside from capturing TGF- beta , TGF-beta RII:Fc may safely be administered during or at the end of retinal reattachment surgery, which is the most common cause of proliferative vitreoretinopathy (PVR) (Connor et al. (1989) J. Clin. Invest. 83:1661-1666). Another important fibroproliferative condition is 5 rheumatoid arthritis (RA), which is also associated with excess TGF- beta production. Data indicate that blocking TGF- beta at any time in the development or chronic stages of RA may help stop the progressive deterioration of the joint and bone. Hence, fusions of the present invention may be administered to patients with early joint pain and to patients with prolonged joint pain and deteriorated joints. The current theory is that joint deterioration in RA is due to 10 an overproduction of TGF- beta . Excess TGF- beta has been measured in joints after test animals are injected with streptococcal cell walls, whose presence is believed to cause rheumatoid arthritis (RA). Because anti-TGF- beta antibody blocks arthritic changes in this model, it is believed that fusions of the invention may also have a positive effect. Other 15 conditions associated with excess TGF- beta levels include idiopathic pulmonary fibrosis and myelofibrosis. To complex with excess TGF- beta and to slow the development of excess fibrous tissue, proteins of the invention are intended for administration in these conditions.

The proteins of the present invention may be used to treat collagen vascular disorders that are associated with overproduction of TGF- beta . It is currently believed that there is an 20 overproduction of TGF- beta in collagen vascular disorders, such as progressive systemic sclerosis (PSS), polymyositis, scleroderma, dermatomyositis, eosinophilic fascitis, and morphea. Collagen vascular disorders may also be associated with the occurrence of Raynaud's syndrome. Among other effects, TGF- beta overproduction may also be involved in interstitial pulmonary fibrosis, an end-stage lung disorder which is associated with autoimmune disorders such as systemic lupus erythematosus (SLE) and scleroderma (Deguchi, (1992) Ann. Rheum. 25 Dis. 51:362-65); or it may be caused by chemical contact, allergies to dust and hay fever. A therapeutically effective amount of the proteins of this invention may be administered to neutralize the biologic activity of TGF- beta , which in turn would prevent unwanted fibrosis.

30 Proteins of the present invention also may be used in preventing overproduction of scarring in patients who are known to form keloids or hypertrophic scars. For example TGF- beta RII:Fc may be administered to prevent scarring or overproduction of scarring during healing of various types of wounds including surgical incisions and traumatic lacerations. The TGF-beta RII:Fc fusion may be applied to skin wounds before they are closed to help in healing without scar formation. Proteins of the invention may be placed in surgical abdominal

wounds to help prevent adhesion formation which occurs all too commonly after that type of surgery. The present invention provides for the local administration of sufficient fusion to complex with local TGF- beta overproduction and prevent overproduction of healing processes.

5        TGF- beta excess also has been reported in nasal polyposis, a condition characterized by multiple polyps (Ohno et al. (1992) *J. Clin. Invest.* 89: 1662-68). Fusion proteins can help lower TGF- beta levels and slow the hyperproliferation that results in polyps. For example, TGF-beta RII:Fc can be administered after polyp surgery to prevent overproduction of scarring and recurrence of polyps and can also be administered to inhibit polyp formation in the  
10        intestine.

15        Proteins of the invention may also be administered following coronary angioplasty, preferably placed along the inside of the affected arteries. According to Karas et al., ((1991) *Clin. Cardiol.* 14:791-801) restenosis or scarring and reclosing of arteries following coronary angioplasty is seen in approximately one-third of patients operated on. Because the fibrous network which ultimately develops into a scar normally accumulates rapidly, early administration of, for instance, TGF-beta RII:Fc would reduce excess TGF- beta in this area and slow excessive proliferation of connective tissue and restenosis.

20        TGF- beta excess has also been observed in cardiac fibrosis after infarction and in hypertensive vasculopathy. To aid in proper healing without excess scar or fibrous tissue formation, proteins of the invention can be administered in these conditions. TGF- beta excess also has been observed in the tissues of patients receiving radiation therapy. Such tissue is characterized by excess connective tissue development, epithelial thinning and blood vessel occlusion associated with overgrowth of endothelial cells. Administration of an TGF-beta RII:Fc will complex with the excess TGF- beta and will contribute to healing without excessive  
25        fibrosis.

#### VI. Formulation, Administration and Dosage

30        The formulation, method of administration and dosage of proteins of the invention will depend upon the disorder to be treated, and the medical history of the patient. These factors are readily determinable in the course of therapy. Suitable patients with conditions caused by an excess of TGF- beta can be identified by laboratory tests, medical history and physical findings. TGF- beta excess can be determined directly by immunoassay of the patient's serum or of the affected tissue. Excess TGF- beta can also be determined by bioassays such as the cell

proliferation assay described in Kekow et al., (1990) Proc. Natl. Acad. Sci. U.S.A. 87: 8321-25.

Excess TGF- beta also can be determined indirectly by measuring the level of TGF- beta mRNA (for example, in the polymerase chain reaction of Kekow et al.).

The medical history may reveal facts which support a diagnosis of fibroproliferative disorder, collagen vascular disorder, immunosuppression, or of potential for problematic wound healing, as in peritoneal adhesions following surgery, or restenosis of blood vessels after coronary angioplasty. Conditions which are identified as being associated with high levels of TGF- beta and/or proliferation of fibrous tissue are considered to cause TGF- beta excess. Patients may have a wide spectrum of physical findings which are indicative of such disorders. Skin biopsies have been used to test TGF- beta in patients with systemic sclerosis. Swollen, hot joints are seen in arthritis. In accordance with the method of the present invention, the formulation comprises proteins of the invention in an administrable form. The method of the present invention provides for formulating proteins of the invention in modes which are readily apparent to those skilled in the art. Preferably, the proteins of the invention are dissolved in physiologically compatible carriers.

Physiologically compatible carriers for proteins of the invention include intravenous solutions, such as normal saline, serum albumin, 5% dextrose, plasma preparations, other protein-containing solutions and TPN solutions. The preferred carrier for parenteral administration is a sterile, isotonic aqueous solution, such as saline or 5% dextrose. Even more preferred is normal saline with human serum albumin. For use in enhancing the immune response to vaccines, proteins of the invention may be mixed with the vaccine formulation.

Depending on the mode of administration, the proteins of the invention may be in the form of liquid or semi-solid dosage preparations, such as for example, liquids, suspensions or the like. Alternatively, a solution may be placed into an implant, such as an osmotic pump, for the slow release over an extended period of time. Alternatively, proteins of the invention may be provided in sustained release carrier formulations such as semi-permeable polymer carriers in the form of suppositories or microcapsules. See, for instance, U.S. Pat. No. 3,773,919 for microcapsular sustained release matrices including polylactides; Sidmon et al., Biopolymers 22 (1), 547-556 (1983) for copolymers of L-glutamic acid and gamma -ethyl-L-glutamate; Langer et al., J. Biomed. Res. 15, 167-277 (1981) for poly(2-hydroxyethylmethacrylate) or the like.

The mode of administration delivers proteins of the invention to the individual in a safe, physiologically effective manner. proteins of the invention may be given by intraocular,

intranasal, subcutaneous, intravenous, intramuscular, intradermal, intraperitoneal, intraarticular, enteral or other conventional routes of administration. In a preferred embodiment, the proteins of the invention of the invention is administered locally to the affected tissue sites by bolus injection or perfusion. For example, for PVR, the preferred mode of administration is a single 5 intraocular injection. Local administration is also preferred in peritoneal wounds to avoid adhesion formation and in other wounds to encourage healing with no keloids or visible scars. For nasal polyposis, nasal drops are preferred. Local and systemic administration are equally preferred in lung fibrosis (parenteral injection or nasal spray or drops). Rheumatoid arthritis (RA) can be treated by intraarticular or systemic administration.

10 Systemic administration is the preferred mode of administration in glomerulonephritis and in widespread skin disorders (such as progressive systemic sclerosis, diffuse fascitis, and generalized morphea). Systemic administration also is preferred when proteins of the invention is used to enhance vaccine response. proteins of the invention can be administered with the vaccine by subcutaneous, intramuscular or intradermal injection.

15 The dose of proteins of the invention to be administered can be readily determined by those

skilled in the art, based on the usual patient symptoms discussed above. The dosage of proteins of the invention to be given in a bolus injection is preferred to be between 20 ng and 300 mg. The bolus injection may be repeated over several days, or the proteins of the invention can be 20 continuously infused. If given as an intravenous infusion, the amount of proteins of the invention to be infused over a 24-hour period is about 1 mg to about 100 mg.

The amount of proteins of the invention to administer may also be determined by maintaining the local tissue concentration of TGF- beta at a subnormal level, or about 1-1,000 mu g/ml..

25 Preferably, proteins of the invention is applied topically, injected at the site of the problem or injected intravenously. Most preferably, proteins of the invention is administered by bolus injection at the site where TGF- beta is to be controlled. By intravenous injection, proteins of the invention should be administered at a rate to maintain a circulating serum concentration sufficient to reduce the TGF- beta excess. Preferably, the patient is started with a 30 relatively low dose of proteins of the invention. The low dose preferably should be continued until the patient's acute phase is ameliorated or adequately improved, as indicated appropriate physical findings and laboratory results. Such improvement may be evident in two to three

weeks. In the absence of significant improvement, the dose of proteins of the invention should be increased.

Gene therapy methods of administering the molecules of the invention are also encompassed within the scope of the invention. The term "transformation" or "transform" refers to 5 any genetic modification of cells and includes both "transfection" and "transduction". As used herein, "transfection of cells" refers to the acquisition by a cell of new genetic material by incorporation of added DNA. Thus, transfection refers to the insertion of nucleic acid (e.g., DNA) into a cell using physical or chemical methods. Several transfection techniques are known to those of ordinary skill. In contrast, "transduction of cells" refers to the process of transferring 10 nucleic acid into a cell using a DNA or RNA virus. One or more isolated polynucleotide sequences encoding one or more TGF-beta RII:Fc proteins contained within the virus may be incorporated into the chromosome of the transduced cell. Alternatively, a cell is transduced with a virus but the cell will not have the isolated polynucleotide incorporated into its chromosomes but will be capable of expressing interferon extrachromosomally within the cell. According to one 15 embodiment, the cells are transformed (i.e., genetically modified) ex vivo. The cells are isolated from a mammal (preferably a human) and transformed (i.e., transduced or transfected in vitro) with a vector containing an isolated polynucleotide such as a recombinant TGF-beta RII:Fc nucleotide operatively linked to one or more expression control sequences for expressing a recombinant secreted protein. The cells are then administered to a mammalian recipient for delivery of the 20 protein in situ. Preferably, the mammalian recipient is a human and the cells to be modified are autologous cells, i.e., the cells are isolated from the mammalian recipient. The isolation and culture of cells in vitro has been reported. According to another embodiment, the cells are transformed or otherwise genetically modified in vivo. The cells from the mammalian recipient (preferably a human), are transformed (i.e., transduced or transfected) in vivo with a vector 25 containing the similar isolated polynucleotide and the protein is delivered in situ.

The isolated polynucleotides encoding the fusion protein are introduced into the cell ex vivo or in vivo by genetic transfer methods, such as transfection or transduction, to provide a genetically modified cell. Various expression vectors (i.e., vehicles for facilitating delivery of the isolated polynucleotide into a target cell) are known to one of ordinary skill in the art. Typically, 30 the introduced material includes an isolated polynucleotide of the invention together with a promoter to control transcription. If delivery of the TGF-beta RII:Fc polynucleotide is to specific tissues, it may be desirable to target the expression of this gene. For instance, there are many promoters described in the literature which are only expressed in certain tissues. Thus, by selecting

-50-

the appropriate promoter (constitutive versus inducible; strong versus weak), it is possible to control both the existence and level of expression of a fusion protein in the genetically modified cell. If the gene encoding the fusion protein is under the control of an inducible promoter, delivery of the protein in situ is triggered by exposing the genetically modified cell in situ to conditions 5 permitting transcription of the protein, e.g., by injection of specific inducers of the inducible promoters which control transcription of the agent. Recently, very sophisticated systems have been developed which allow precise regulation of gene expression by exogenously administered small molecules. These include, the FK506/Rapamycin system (Rivera et al., Nature Medicine 2(9): 1028-1032, 1996); the tetracycline system (Gossen et al., Science 268: 1766-1768, 1995), the 10 ecdysone system (No et al., Proc. Nat. Acad. Sci., USA 93: 3346-3351, 1996) and the progesterone system (Wang et al., Nature Biotechnology 15: 239-243, 1997).

Accordingly, the amount of fusion protein that is delivered in situ is regulated by controlling such factors as: (1) the nature of the promoter used to direct transcription of the inserted polynucleotide (i.e., whether the promoter is constitutive or inducible, strong or weak or 15 tissue specific); (2) the number of copies of the exogenous polynucleotide that are inserted into the cell; (3) the number of transduced/transfected cells that are administered (e.g., implanted) to the patient; (4) the size of an implant (e.g., graft or encapsulated expression system) in ex vivo methods; (5) the number of implants in ex vivo methods; (6) the number of cells transduced/transfected by in vivo administration; (7) the length of time the transduced/transfected 20 cells or implants are left in place in both ex vivo and in vivo methods; and (8) the production rate of the fusion protein by the genetically modified cell.

Expression vectors compatible with mammalian host cells for use in gene therapy include, for example, plasmids; avian, murine and human retroviral vectors; adenovirus vectors; herpes viral vectors; parvoviruses; and non-replicative pox viruses. In particular, replication-25 defective recombinant viruses can be generated in packaging cell lines that produce only replication-defective viruses. See **Current Protocols in Molecular Biology**: Sections 9.10-9.14 (Ausubel et al., eds.), Greene Publishing Associates, 1989. Specific viral vectors for use in gene transfer systems are now well established. See for example: Madzak et al., J. Gen. Virol., 73: 1533-36 (1992) (papovavirus SV40); Berkner et al., Curr. Top. Microbiol. Immunol., 158: 39-61 (1992) (adenovirus); Moss et al., Curr. Top. Microbiol. Immunol., 158: 25-38 (1992) (vaccinia virus); Muzyczka, Curr. Top. Microbiol. Immunol., 158: 97-123 (1992) (adeno-associated virus); Margulies, Curr. Top. Microbiol. Immunol., 158: 67-93 (1992) (herpes simplex virus (HSV) and 30

-51-

Epstein-Barr virus (HBV)); Miller, Curr. Top. Microbiol. Immunol., 158: 1-24 (1992) (retrovirus); Brandyopadhyay et al., Mol. Cell. Biol., 4: 749-754 (1984) (retrovirus); Miller et al., Nature, 357: 455-450 (1992) (retrovirus); Anderson, Science, 256: 808-813 (1992) (retrovirus). Preferred vectors are DNA viruses that include adenoviruses (preferably Ad-2 or Ad-5 based vectors), 5 herpes viruses (preferably herpes simplex virus based vectors), and parvoviruses (preferably "defective" or non-autonomous parvovirus based vectors, more preferably adeno-associated virus based vectors, most preferably AAV-2 based vectors). See, e.g., Ali et al., Gene Therapy 1: 367-384, 1994; U.S. Patent 4,797,368 and 5,399,346 and discussion below.

Adeno-associated viruses (AAV) have also been employed as vectors for somatic gene 10 therapy. AAV is a small, single-stranded (ss) DNA virus with a simple genomic organization (4.7 kb) that makes it an ideal substrate for genetic engineering. Two open reading frames encode a series of *rep* and *cap* polypeptides. *Rep* polypeptides (*rep78*, *rep68*, *rep 62* and *rep 40*) are involved in replication, rescue and integration of the AAV genome. The *cap* proteins (VP1, VP2 and VP3) form the virion capsid. Flanking the *rep* and *cap* open reading frames at the 5' and 3' 15 ends are 145 bp inverted terminal repeats (ITRs), the first 125 bp of which are capable of forming Y- or T-shaped duplex structures. Of importance for the development of AAV vectors, the entire *rep* and *cap* domains can be excised and replaced with a therapeutic or reporter transgene. See B.J. Carter, in Handbook of Parvoviruses, ed., P. Tijsser, CRC Press, pp. 155-168 (1990). It has been shown that the ITRs represent the minimal sequence required for replication, rescue, 20 packaging, and integration of the AAV genome. The AAV life cycle is biphasic, composed of both latent and lytic episodes. During a latent infection, AAV virions enter a cell as an encapsidated ssDNA, and shortly thereafter are delivered to the nucleus where the AAV DNA stably integrates into a host chromosome without the apparent need for host cell division. In the absence of a helper virus, the integrated AAV genome remains latent but capable of being activated and rescued. The 25 lytic phase of the life cycle begins when a cell harboring an AAV provirus is challenged with a secondary infection by a herpesvirus or adenovirus which encodes helper functions that are required by AAV to aid in its excision from host chromatin (B.J. Carter, *supra*). The infecting parental single-stranded (ss) DNA is expanded to duplex replicating form (RF) DNAs in a *rep* dependent manner. The rescued AAV genomes are packaged into preformed protein capsids 30 (icosahedral symmetry approximately 20 nm in diameter) and released as infectious virions that have packaged either + or - ssDNA genomes following cell lysis. AAV have significant potential in gene therapy. The viral particles are very stable and recombinant AAVs (rAAV) have "drug-

"like" characteristics in that rAAV can be purified by pelleting or by CsCl gradient banding. They are heat stable and can be lyophilized to a powder and rehydrated to full activity. Their DNA stably integrates into host chromosomes so expression is long-term. Their host range is broad and AAV causes no known disease so that the recombinant vectors are non-toxic. Recently, 5 recombinant baculovirus, primarily derived from the baculovirus *Autographa californica* multiple nuclear polyhedrosis virus (AcMNPV), has been shown to be capable of transducing mammalian cells in vitro. (See Hofmann, C., Sandig, V., Jennings, G., Rudolph, M., Schlag, P., and Strauss, M. (1995), "Efficient gene transfer into human hepatocytes by baculovirus vectors", Proc. Natl. Acad. Sci. USA 92, 10099-10103; Boyce, F.M. and Bucher, N.L.R. (1996) "Baculovirus-mediated 10 gene transfer into mammalian cells", Proc. Natl. Acad. Sci. USA 93, 2348-2352). Recombinant baculovirus has several potential advantages for gene therapy. These include a very large DNA insert capacity, a lack of a pre-existing immune response in humans, lack of replication in mammals, lack of toxicity in mammals, lack of expression of viral genes in mammalian cells due to the insect- specificity of the baculovirus transcriptional promoters, and, potentially, a lack of a 15 cytotoxic T lymphocyte response directed against these viral proteins

The invention will be illustrated by the following, non-limiting examples.

**Example 1: Construction and Expression of Soluble Rabbit TGF $\beta$ R:Fc Fusion Protein**

A full length clone (MIS\_3f11), encoding the rabbit Type II TGF-beta ("TGF $\beta$ ) receptor, is isolated from a rabbit ovary cDNA library as described (di Clemente et al., *Mol. Endocrinol.* 8:1006 [ 1994]). The recombinant rabbit TGF $\beta$ RII:Fc fusion gene, consisting of the extracellular domain of the rabbit type II receptor (Nucleotide 832-1311 from SEQ ID NO.: 2) fused to the Fc portion of human IgG1 (Nucleotide 1312-1995 from SEQ ID NO.: 2), is constructed as follows:

25 Fragment 1) a 479 bp fragment , containing the extracellular domain of the rabbit TGF $\beta$  type II receptor, is amplified from clone MIS\_3f11 by conventional PCR using the appropriate oligonucleotide primers (SEQ ID NO.: 5 and SEQ ID NO.: 6). These oligonucleotides confer flanking Not1 and Sal1 restriction enzyme sites on the resulting PCR product, which is subsequently digested with these two restriction enzymes.

30 Fragment 2) pSAB132 (Miller et al., *J. Exp. Med.* 178:211 [1993]) is digested with the restriction enzyme Not1, and the terminal phosphate groups are removed by digestion with calf alkaline intestinal phosphatase.

-53-

5        Fragment 3) pSAB144 is constructed. The human IgG1 heavy (H) chain constant region containing the hinge region, the C<sub>H</sub>2 and the C<sub>H</sub>3 sequences, are isolated with H chain-specific primers by PCR amplification of cDNA from the RNA of COS-7 cells that had been transfected with plasmids containing 3 kilobase pair genomic inserts (Miller et al., *J. Exp. Med.* 178:211 [1993]). Heavy chain specific oligonucleotides primers are designed so that the resulting C<sub>H</sub>2 and C<sub>H</sub>3IgG1 PCR amplified sequences were flanked by a 5' Sal1 and a 3' Not1 restriction enzyme recognition site. pSAB144 is digested with the restriction enzymes Not1 and Sal1 to release a 700 base pair fragment containing the Fc portion of human IgG1.

10      Fragments 1,2, and 3 are ligated together, and transformed into transformation competent bacteria. Plasmids are recovered from the transformants and analyzed by restriction enzyme digestions and gel electrophoresis for the correct orientation of assembled fragments. This construct is comprises the recombinant rabbit TGF $\beta$ RII:Fc fusion gene, and the entire coding sequence is confirmed by DNA sequencing (SEQ ID NO.: 1 and 2).

15      The recombinant rabbit TGF $\beta$ RII:Fc fusion gene is transfected into Chinese hamster ovary (CHO) cells by electroporation at 280 volts. After the initial transfection, cells are selected for the expression dihydrofolate reductase (DHFR) by subculturing in selective medium lacking glycine, hypoxanthine, and thymidine. The resulting colonies are then transferred to 24 well plates and analyzed for rabbit TGF $\beta$ R:Fc fusion gene expression. The highest expressing cultures are subjected to amplification by exposure to increasing amounts 20 of methotrexate. Cells able to grow at 25 nM methotrexate are cloned by limiting dilution in 96 well plates. The highest expressing clones are transferred to suspension culture and the clone expressing the highest levels of TGF $\beta$ RII:Fc is selected for production of TGF $\beta$ RII:Fc.

25      Those proficient in the art can construct and express a similar recombinant gene containing the extracellular domain of the human TGF $\beta$  type II receptor by isolating the human type II TGF $\beta$  receptor gene from commercially available human ovary cDNA (Clontech) and substituting the oligonucleotide primer described in SEQ ID NO.: 7 for the oligonucleotide primer described in SEQ ID NO.: 6. The DNA sequence of the resulting human TGF $\beta$ R:Fc fusion gene is described (SEQ ID NO.: 3 and SEQ ID NO. 4).

30

**Example 2: The TGF $\beta$ R:Fc Fusion Protein binds TGF $\beta$  in vitro.**

The recombinant rabbit TGF $\beta$ R:Fc fusion gene (SEQ ID NO: 2 contained within expression vector SEQ ID NO.: 1) is transfected into COS cells by electroporation at 280 volts. Transfected cells are grown in DMEM, supplemented with 10% fetal bovine serum. After 5 days, the cells are removed from the culture by centrifugation and the supernatant is assessed 5 for the expression of recombinant rabbit TGF $\beta$ RII:Fc by SDS/Polyacrylamide gel electrophoresis (SDS/PAGE). TGF $\beta$ RII:Fc present in the cell culture supernatant is tested for the ability to bind TGF $\beta$ . [ $^{125}$ I]-TGF $\beta$  (NEN Life Science Products) is incubated for 2.5 hours with conditioned cell culture medium containing rabbit TGF $\beta$ RII:Fc, or control IgG, and Protein A-Sepharose which binds to the Fc portion of IgG. The resulting Protein A: Fc 10 complexes are recovered by centrifugation, washed in phosphate buffered saline, and analyzed by SDS/PAGE and autoradiography. TGF $\beta$ RII:Fc, but not control IgG immunoprecipitates [ $^{125}$ I]-TGF $\beta$ .

#### **Example 3: Mink Lung Cell Proliferation Assay**

15 The proliferation of mink lung epithelial cells (CCL64) is inhibited by TGF $\beta$ 1. Thus, we can test the ability of TGF $\beta$ R:Fc to block the anti-proliferative effect of TGF $\beta$ 1. CCL64 cells are maintained in MEM supplemented with 100 units/ml penicillin, 100  $\mu$ g/ml streptomycin, and 10% fetal bovine serum. To test, serial dilutions of TGF $\beta$ R:Fc are incubated with 0.1 ng/ml TGF $\beta$ 1 for 1 hr in assay medium (MEM supplemented with 100 20 units/ml penicillin, 100  $\mu$ g/ml streptomycin, and 10% fetal bovine serum) in a 96-well microtiter tissue culture plate. CCL64 cells are resuspended in assay medium and added to the assay plate at a concentration of 4000 cells per well. The cells are incubated at 37 degrees C for 72 hours and pulsed with [ $^3$ H] thymidine (70-86 Ci/mmol) for an additional 4 hours. DNA synthesis, which reflects cell proliferation, is determined by measuring incorporation of [ $^3$ H] thymidine. When cell are allowed to proliferate in media alone, the amount of [ $^3$ H] thymidine 25 incorporated is measured as 188,745 counts per minute (CPM). When TGF $\beta$ 1 is included in the media, proliferation is inhibited, and the amount of [ $^3$ H] thymidine incorporated is measured as 49088 counts per minute. Below, the results are shown when increasing amounts of TGF $\beta$ R:Fc or control IgG are added to the media:

30

<u>Concen.</u> <u><math>\mu</math>g/ml</u>	<u>TGF<math>\beta</math>RII:</u> <u>Fc (CPM)</u>	<u>Control</u> <u>IgG</u>
---	---	------------------------------

-55-

		<u>(CPM)</u>
10	181933	53619
5	179461	55097
2.5	178770	54443
1.25	168020	51443
0.62	150106	56683
0.31	118613	52415
0.16	75112	52830
0.08	63841	61894
0.04	49929	54395
0.02	57685	42993

The amount of TGF $\beta$ RII:Fc required to inhibit the anti-proliferative effect of 0.1 ng/ml TGF $\beta$ 1 by 50% equals 0.5  $\mu$ g/ml.

5   **Example 4: Rat Vessel Injury Model**

Male Sprague-Dawley rats weighing 400g and about 3-4 months of age (Bantin & Kingman, Edwards, WA) were used throughout. All surgical procedures are carried out under general anesthesia by intraperitoneal injection of xylazine (2.2 mg/kg, AnaSed TM, Lloyd Laboratories, Shenandoah, IA) and ketamine (540 mg/kg, Ketaset TM, Aveco Co., Fort Dodge, IA). The left common carotid artery is denuded with a 2F balloon catheter by introducing the catheter through the external carotid artery. The distal left common carotid and external carotid arteries are exposed through a midline wound in the neck. The catheter is passed three times with the balloon distended sufficiently with saline to generate slight resistance; this method produces distension of the carotid itself. The external carotid is ligated after removal of the catheter and the wound closed.

Experimental treatments include a series of 1 ml intravenous injection of TGF-beta Type II receptor:Fc (SEQ ID NO: 8) in PBS given every other day (post-operation) at 5 mg/kg. After 14 days post balloon catheter denudation, all rats are anesthetized and the carotid arteries fixed by perfusion at 120 mm Hg pressure with 1% paraformaldehyde and 1.25% glutaraldehyde in 20 0.1M phosphate buffer, pH 7.4 via a large cannula placed retrograde in the abdominal aorta. Ten minutes before fixation, these animals are given an intravenous injection of Evans blue (0.3 ml in 5% saline solution). After 5 minutes of perfusion, the entire left and right common carotid

-56-

arteries are retrieved, includigin the aortic arch. The vessels are further fixed by immersion in the same fixative as was used for perfusion..

Arterial segments are assayed for the presence or absence of endothelium by obtaining three segments from the denuded, blue-stained left carotid artery and emdedding them in paraffin 5 for cross sectioning using a "Micron" microtome. For measuring intimal areas, photomicrographs are obtained from 3-4 sections from each animal. The photomicrographs are digitized and anlaysed with image analyusis software (NIH Image 1.55 for MacIntosh). Intimal areas are measured by determining the area between liumen and internal elastic lamina. Medial areas are derermined bymeasuring the area beween internal and external elastic lamina.

10 Intimal/medial area ratios are calculated form the measurements.

**Effect of TGF-beta RII:Fc (SEQ ID NO: 8) on Re-Stenosis in Rat Model**

**Table 1: Intimal area (mm<sup>2</sup>)**

Treatment	Mean Area	Std. Dev	Std. Error.
<b>Control (n=4)</b>	<b>0.15</b>	<b>0.015</b>	<b>0.008</b>
<b>Experimental:</b> <b>5 mg/kg/dose</b> <b>35 mg/kg per course of</b> <b>therapy (n=5)</b>	<b>0.068</b>	<b>0.016</b>	<b>0.007</b>

An unpaired T-test between treatments resulted in a statistically significant p= 0.0001.

**Table 2: Intimal/Medial area ratios**

Treatment	Mean Ratio	Std. Dev.	Std. Error
<b>Control (n=4)</b>	<b>0.706</b>	<b>0.03</b>	<b>0.015</b>

-57-

<b>Experimental:</b>	<b>0.360</b>	<b>0.137</b>
<b>5 mg/kg/dose</b>		
<b>35 mg/kg per course of</b>		
<b>therapy (n=5)</b>		

An unpaired t-Test between treatments resulted in a statistically significant  $p= 0.0018$ , indicating that treatment with SEQ ID NO: 8 significantly reduced the formation of intima relative to the media as compared to non-treated groups.

**Example 5: Lung Fibrosis Model**

An excess accumulation of collagen in the lungs is a hallmark of lung fibrosis. The amount of collagen in tissue depends on the rate of collagen synthesis and collagen degradation 10 and in cases of fibrosis, the rate of collagen synthesis predominates the rate of collagen degradation.

Chronic respiratory disease free Golden Syrain hamster weighing 120-130g are purchased from Charles River (Boston, MA) and housed in plastic cages in groups of 4 in facilities approved by the American Association for Accreditation of Laboratory Animal Care. The animals are 15 allowed to acclimate for one week to laboratory conditions prior to starting the experiments. They have access to Rodent Laboratory Chow 5001 (Purina Mills, Inc., St. Louis, MO) and water *ad libitum* and housed in a room which gets the filtered air and has 12hr/12hr light/dark cycle. Hamsters will be assigned into the following groups for the biochemical and histopathological studies.

	Treatment Group	Biochemical Study (n)	Histopathology Study (n)
20	Saline IT + Saline IP	10	6
	Bleomycin IT + saline IP	10	6
	Bleomycin IT + TGF-beta Type II receptor:Fc	10	6

Saline IT + TGF-beta receptor

10

6

Type II: Fc

Bleomycin sulfate is dissolved in pyrogen free sterile isotonic saline just before intratracheal (IT) instillation. Under pentobarbital anesthesia (25-35mg/kg ip) hamsters in appropriate group receive either bleomycin (5.5 units/kg/4ml) or an equivalent volume (4ml/kg) of 5 pyrogen free isotonic saline through transoral route. The TGF- $\beta$  Type II receptor:Fc is administered by intraperitoneal (IP) or intratrachial route at a therapeutic dose to hamster in appropriate groups twice a week for 21-28 days post installation. Thereafter, the animals in each group are killed by an overdose of sodium pentobarbital (100-125 mg/kg ip) and their lungs processed for biochemical and histopathological studies.

10

1. Biochemical Study

The lungs of animals used for biochemical studies are perfused *in situ* via the right ventricle with ice-cold isotonic saline to wash out blood from the pulmonary vasculature through an opening in the left ventricle. The lung lobes are quickly dissected free of non-parenchymal 15 tissue, dropped in liquid nitrogen for quick freezing and then stored at -80C. The frozen lungs are later thawed and homogenized in 0.1 M KC, 0.02 M Tris buffer (pH 7.6) with a Polytron homogenizer. Several 1 ml aliquots of the homogenate are stored at -80C until the time various biochemical assays are carried out.

Hydroxyproline content of the lung homogenate as a measure of collagen content is 20 quantitated by the techniques of Woessner, Arch. Biochem. Biophys. 93: 440-447 (1961) and lipid peroxidation by the method as described in Giri, et al.,, Biochem. Pharmacol. 54: 1205-1216 (1997).

2. Histopathological Study

25 Hamsters are anesthetized to a level of cardiac cessation. The thorax is opened, the heart tied off at its base and the trachea cannulated. The lungs and heart will be removed *en bloc*, weighed and placed in a normal saline bath and the lungs instilled with a 1% glutaraldehyde-parafomaldehyde fixative in 0.12M cacodylate buffer at 400m Osm at 30 cm H<sub>2</sub>O pressure. The lungs are fixed via this pressure for about 2 hours and then stored in fixative with the tracheas

-59-

occluded. Before embedding, the lung is isolated from the heart and all non-pulmonary tissue by blunt dissection and removed. Blocks of tissue are cut from at least two sagittal slabs (2-3mm thick) from the right cranial, right caudal, and left lung lobes of each lung. Each block is cut with about a 1 cm<sup>2</sup> face. The blocks are dehydrated in a graded series of ethanol and embedded in 5 paraffin. Sections (5µm thick) are cut from the paraffin blocks and stained with haematoxylin and eosin for histological evaluations.

3. Data Analysis and Interpretation

The values for different biochemical determinants in the lungs of control and treated 10 animals are expressed per mg lung protein or DNA. However, it should be noted that the expression of the data based on per mg of lung protein or DNA will tend to introduce artificial lowering of the values in treated animals. This problem is attributed to the infiltration of leukocytes, presence of residual plasma protein in the lungs even after perfusion, and proliferation of type II cells and fibroblasts in a long term study in the lungs of hamster treated with bleomycin. In order to avoid 15 an artificial lowering of the values, the data will be expressed on a per lung basis. See Starcher et al., Am. Rev. Resp. Dis., 117:299-305 (1973) and Witschi, Essays Toxicol., 6:125-191 (1975).

The data are analyzed in terms of average values with their standard deviations and 20 standard errors of means. Student's t-test, chi-square distributions, correlation coefficient, analysis of variance (ANOVA) and multiple comparison test will be applied to judge the significance of differences between the control and treatment groups using a computer based statistical package (SAS/STAT Guide, 6th Ed. Cary, N.C. pp. 183-260 (1985)).

**Example 6: Glomerulonephritis Model**

25 The effect of proteins of the invention is assessed in a glomerulonephritis model. Experimental glomerulonephritis is induced in rats with a single injection of anti-glomerular basement membrane nephrotxin serum (NTS), derived in rabbits. The experimental lesion is acute mesangial proliferative glomerulonephritis and is characterized by expansion of the mesangial matrix and hypercellularity. The injured cells also express more TGF- beta 1 mRNA 30 and TGF- beta 1, which in turn stimulates the synthesis of two proteoglycans, biglycan and decorin. Of particular interest, the nephritis reproducibly progresses through glomerular and tubulointerstitial scarring, to end stage renal disease.

-60-

First, glomerulonephritis is induced in rats by an intravenous injection of NTS serum. Next, for six days, two groups of rats are treated with daily intravenous injections of saline (the negative control group) or proteins of the invention. On the tenth day, the animals are sacrificed and slides are made of the kidneys, which are stained with periodic acid-Schiff solution to emphasize the pathological changes. The negative control kidneys have full-blown glomerulonephritis with reddish-pink amorphous fibrous material filling most of the glomerulus. The positive control kidneys have a staining pattern which is similar to a normal glomerulus. The kidney which is treated with proteins of the invention also has a normal appearance, indicating that the proteins of the invention blocks the response due to the secretion of overproduction of TGF- beta .

The extent of glomerular injury can be quantitated by performing glomerular cell counts from 30 randomly selected glomeruli from normal animals and nephritic animals in each group. By day 10, there are more cells in glomeruli from NTS-treated rats. Kidney function is also assessed by measuring levels of albumin in urine and by quantitating creatinine clearance.

Another measure of the effect of proteins of the invention on the disease process is to quantitate the amount of extracellular matrix accumulation in the glomeruli. The degree of glomerular matrix expansion is determined as the percentage of each glomerulus occupied by the mesangial matrix according to the method of Raij et al. (1984) Kidney Int. 26: 137-43. The TGF- beta RII:Fc-treated kidneys are expected to have similar percentages of mesangial matrix to that in normal kidney, and significantly less mesangial matrix than in the negative control kidneys.

#### Example 7: Arthritis Model

Arthritis is induced in pathogen-free female LEW rats (Harlan Sprague Dawley, Indianapolis, Ind.) weighing about 100 grams. Each receives a dose of cell wall fragments from Group A streptococci (SCW) (30 mu g rhamnose/gm bodyweight), injected intraperitoneally (ip) according to the technique described in Brandes et al. (1991) J. Clin. Invest. 87:1108. SCW-injected and control LEW rats are given an intraarticular (IA) injection in one of the hind ankles of one of the following:

- 30 1. proteins of the invention in 25 mu l PBS,
2. PBS only, or
3. an IgG control

-61-

Joints are clinically monitored by determining the amount of joint erythema, swelling and distortion on a scale of 0 (normal) to 4 (severe inflammation). Radiographs are taken and are evaluated for soft tissue swelling, joint space narrowing, bone erosions and deformity. Tissue specimens are obtained and prepared for histopathologic analysis as described in 5 Brandes et al., ibid. Total RNA is isolated from excised synovial tissues according to the method of Allen et al. (1990) J. Exp. Med. 171:231.

Injection of SCW produces an acute inflammatory response which is clinically detectable within hours and maximal in 3-5 days. When TGF-beta Type II receptor:Fc is injected directly into a joint before ip administration of the SCW, inflammation at 24 hours is significantly 10 below that observed in joints with the irrelevant antibody. At the peak of the acute response, inflammation of such treated joints remains far below that of joints with the irrelevant antibody. Even if joints are injected with TGF-beta Type II receptor:Fc when inflammation is well developed (day 13), the fusion still has a significant anti-inflammatory effect, when 15 compared to irrelevant antibody. Because proteins of the invention also bind TGF-beta, they have a similarly beneficial effect when given early or late in the inflammatory process. Other well established experimental models of RA include collagen and adjuvant-induced arthritis. See, for example Janusz MJ et al., Inflamm Res. 46:503-508 (1997); Myers et al., Life Sci 61:1861-1878 (1997); and Kock et al., Clin Immunol Immunopathol 86: 199-208 (1998).

20 EQUIVALENTS

This invention has been detailed both by example and by direct description. It should be apparent that one having ordinary skill in this art would be able to surmise equivalents to the invention as described in the claims which follow but which would be within the spirit of the description above. Those equivalents are to be included within the scope of this invention.

-62-

What is claimed is:

1. An isolated TGF-beta receptor fusion protein that competitively inhibits binding of TGF-beta to TGF-beta receptor.

5

2. The fusion protein of claim 1, comprising TGF-beta Type II receptor linked to a second protein that is not a TGF-beta Type II receptor.

10

3. The fusion protein of claim 2, wherein the second protein is a constant region of an immunoglobulin.

15

4. The fusion protein of claim 3, comprising SEQ ID NO: 8 or SEQ ID NO.: 9.

5. An isolated TGF-beta receptor fusion protein comprising amino acids 1 to 160 of SEQ ID NO: 8.

15

6. An isolated TGF-beta receptor fusion protein comprising amino acids 1 to 160 of SEQ ID NO: 9.

20

7. The isolated protein of claims 5 or 6, wherein the amino acids are linked to at least a portion of a constant region of an immunoglobulin.

25

8. An isolated polynucleotide encoding, on expression, for an TGF-beta Type II receptor linked to a second protein that is not a TGF-beta Type II receptor.

25

9. The isolated polynucleotide of claim 8, selected from the group consisting of:

(a) SEQ ID NOS.: 10 or 12; (b) a polynucleotide that hybridizes to the foregoing sequence under standard hybridization conditions and that encodes a protein having the TGF-beta inhibitory activity of a TGF-beta Type II receptor fusion protein; and (c) a polynucleotide that codes on expression for a protein encoded by any of the foregoing polynucleotide sequences.

-63-

10. A composition comprising a TGF-beta receptor fusion protein in a pharmaceutically acceptable carrier, the fusion protein in an amount sufficient to competitively inhibit binding of TGF-beta to a TGF-beta ligand.

5 11.. A vector comprising the polynucleotide sequence of claim 9.

12. A host cell containing the vector of claim 11.

10 13. A method for producing a TGF-beta receptor fusion protein, comprising culturing the host cell of claim 12, allowing said cell to express the fusion protein, isolating and purifying the fusion protein.

15 14. A method for lowering the levels of TGF-beta in an individual in need thereof which comprises administering to said individual a TGF-beta-lowering amount of a TGF-beta antagonist that is a TGF-beta receptor fusion protein comprising the sequence of amino acids of SEQ ID NOS: 8 or 9.

20 15. A method for lowering the levels of TGF-beta in an individual having arthritis, which comprises administering to said individual an effective amount of a TGF-beta antagonist that is a TGF-beta receptor fusion protein comprising the sequence of amino acids of SEQ ID NOS: 8 or 9.

25 16. A method for treating an individual for a medical condition associated with TGF-beta overproduction comprising the step of administering to the individual a TGF- beta Type II receptor fusion protein having an amino acid sequence shown SEQ ID NOS: 8 or 9 in an amount sufficient to reduce the activity of TGF- beta in said individual.

30 17. The method of claim 16, wherein the TGF- beta receptor fusion protein is administered by a method selected from the group consisting of intravenous, intraocular, intraarticular, transdermal, and enteral administration.

18. The method of claim 16, wherein said medical condition comprises a fibroproliferative disorder.

-64-

19. The method of claim 18, wherein said fibroproliferative disorder comprises a fibrosis selected from the group consisting of kidney, intraocular, and pulmonary fibrosis.
20. The method of claim 18, wherein said fibroproliferative disorder is selected from the group consisting of diabetic nephropathy, glomerulonephritis, proliferative vitreoretinopathy, and myelofibrosis.
21. The method of claim 18, wherein said fibroproliferative disorder is a collagen vascular disorder selected from the group consisting of systemic sclerosis, polymyositis, scleroderma, dermatomyositis, or systemic lupus erythematosus.

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/07587

**A. CLASSIFICATION OF SUBJECT MATTER**  
 IPC 6 C12N15/62 C07K14/71 A61K38/17

According to International Patent Classification(IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
 IPC 6 C12N C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	OKADOME T ET AL: "Distinct roles of the intracellular domains of transforming growth factor-beta type I and type II receptors in signal transduction." J BIOL CHEM, DEC 9 1994, 269 (49) P30753-6, XP002077575 UNITED STATES see the whole document	1,2,5,6, 8-13
Y	WO 94 17828 A (BIOGEN INC ;BURKLY LINDA C (US)) 18 August 1994 see claims 1-17; figure 8; example 5 -/-	3,4,7, 14-21
Y	-----	3,4,7, 14-21

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

**\* Special categories of cited documents :**

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

22 September 1998

Date of mailing of the international search report

01/10/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.  
Fax: (+31-70) 340-3016

Authorized officer

Nauche, S

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/07587

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>ANDERS RA ET AL: "Chimeric granulocyte/macrophage colony-stimulating factor/transforming growth factor-beta (TGF-beta) receptors define a model system for investigating the role of homomeric and heteromeric receptors in TGF-beta signaling."</p> <p>J BIOL CHEM, SEP 6 1996, 271 (36) P21758-66, XP002077576</p> <p>UNITED STATES see the whole document</p> <p>-----</p>	1-21
A	<p>WO 96 26964 A (PROTEIN DESIGN LABS INC ; IOWA IMMUNOTHERAPY INVESTIGATO (US)) 6 September 1996</p> <p>see the whole document</p> <p>-----</p>	3,4,7, 14-21

**INTERNATIONAL SEARCH REPORT**

International application No.

PCT/US 98/07587

**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.:

because they relate to subject matter not required to be searched by this Authority, namely:

Remark: Although claim 14-21 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

2.  Claims Nos.:

because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out. Specifically:

3.  Claims Nos.:

because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II Observations where unity of invention is lacking(Continuation of item 2 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

**Remark on Protest**

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International Application No

PCT/US 98/07587

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9417828	A 18-08-1994	AT	161730 T	15-01-1998
		AU	687790 B	05-03-1998
		AU	6237994 A	29-08-1994
		AU	6984698 A	23-07-1998
		CA	2155303 A	18-08-1994
		DE	69407758 D	12-02-1998
		DE	69407758 T	27-08-1998
		EP	0682529 A	22-11-1995
		ES	2114183 T	16-05-1998
		JP	8508719 T	17-09-1996
		NZ	262615 A	27-02-1996
WO 9626964	A 06-09-1996	AU	5090496 A	18-09-1996
		CA	2212750 A	06-09-1996
		EP	0812333 A	17-12-1997